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INTRODUCTION 
          Gastric cancer is the third most common cancer in India and the second 
most common type of cancer worldwide
1
. Approximately 800,000 new cases 
are diagnosed every year, despite a steadily declining incidence over the 
previous 50 years
2
. There is wide variation in incidence in different continents. 
The highest incidence of gastric cancer is in Asia
3,4
, Central Europe, and South 
America. There have also been changes noted in the topographic distribution of 
gastric cancer in recent years. The incidence of proximal gastric tumors
5,6
 has 
been on the rise. The widespread use of upper GI endoscopy has led to more 
frequent detection of superficial cancers. This trend has had a dramatic impact 
on the mortality rate, to the point that gastric cancer is now considered 
potentially curable when detected at an early stage
7
. 
 Gastric carcinoma exhibits a wide range of morphological phenotypes. 
The histological appearances of tumor cannot fully reveal the prognosis. The 
prognosis of gastric carcinoma is mainly dependent on the stage of the disease. 
Because of the variability of prognosis within a clinical or pathological stage of 
gastric cancer, there has been a constant search for specific biological markers 
in order to identify subgroups of patients with more aggressive course of 
disease
8
. The immunohistochemical protein expression of p53 and Ki-67 has 
been proposed as a potential tool for the evaluation of the biological behavior of 
gastric cancer
9
. 
1
Mutations of the p53 gene have been found in a number of 
malignancies
10-17
. In contrast to the normal p53 protein, the mutated p53 protein 
has an increased half-life and hence accumulates within the cell nucleus. This 
can be detected immunohistochemically using monoclonal antibodies. 
Cell proliferation can be assessed by immuno-histochemical staining with 
proliferation markers such as Ki-67 antigen. The monoclonal antibody MIB – 1 
reacts with nuclear antigen present throughout the cell cycle of proliferating 
cells but absent in quiescent cells
18
. The level of Ki 67 immuno-reactivity 
correlates with the degree of tumour proliferation
18
. 
Patients expressing high levels of p53 and Ki-67 have poorer prognosis 
because of an aggressive tumour behavior, independent of the already known 
adverse predictors. Thus the routine evaluation of p53 and Ki -67 could be 
useful in identifying patients with more aggressive disease and contribute to a 
better therapeutic approach.  
In this study of 50 cases, an attempt is made to study the expression of 
p53 and Ki-67 immunohistochemically and compare it with various clinico-
pathological parameters. 
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AIMS AND OBJECTIVES 
1. To identify the incidence and distribution of gastric carcinoma in patients 
admitted in Government General Hospital, Chennai during the year 2010. 
2. To study the histo-morphological features of gastric carcinoma including 
tumour size, tumour location, macroscopic appearance, histological type, 
grade, depth of infiltration, lymph node status, stage , lympho-vascular 
invasion, perineural infiltration, lymphocytic response, and necrosis.  
3. To study the immunohistochemical expression of p53 in gastric 
carcinoma 
4. To study the immunohistochemical expression of Ki-67 in gastric 
carcinoma 
5. To determine the correlation of  p53 and Ki 67 expression with  known 
prognostic factors such as tumor size, histological type, grade, depth of 
infiltration,  lymph node status, stage, presence of tumor necrosis, 
lymphocytic response, lympho-vascular invasion and perineural 
infiltration. 
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REVIEW OF LITERATURE 
Gastric carcinomas are a group of malignant tumours of the stomach 
arising from the gastric glandular epithelium.  
The first case of gastric cancer was reported in the Ebers papyrus in 1600 
BC and in the Hippocrates reports related by Galen in the second century AD in 
Rome
19
. At the end of the first millennium AD, a possible description of a 
gastric cancer could be read in Avicenna‟s Medical Encyclopedia. Despite this, 
in the eighteenth century, gastric cancers were largely unknown because benign 
and malignant gastric ulcers were only described later by J. Cruveilhier, in 
1835. 
The official history of gastric cancer surgery began 40 years later when 
Jules Emile Pean, a very famous French surgeon, performed the first gastric 
resection for cancer in 1879
20
. The first successful subtotal resection with 
gastro-duodenal anastomosis was performed by Theodor Billroth in 1881 in 
Vienna
21
.  
Later several classification systems were proposed. One of the earliest 
was the Lauren classification proposed in 1965 which divided gastric 
adenocarcinomas into 2 types – Intestinal and Diffuse22. This was followed by 
the Ming classification in 1977 which divided the adenocarcinomas into 2 types 
– expanding and infiltrative, based on the growth pattern23. The WHO 
4
classification was proposed in 1977 which was based on the histomorphology
24 
(Annexure II). 
Epidemiology: 
In 2000, about 880 000 people were diagnosed with gastric cancer and 
approximately 650 000 died of the disease world wide
2
. Japan and Korea have 
the highest gastric cancer rates in the world
25,26
. Age-standardized incidence 
rates in Japan are 69.2 per 100,000 in men and 28.6 per 100,000 in women
27
. 
In India there is a wide variation in the incidence of gastric carcinoma. 
According to the study conducted by the National Cancer Registry Programme 
of India in 2001, the number of new gastric cancer cases  was estimated to be 
approximately 35,675 (n=23,785 in men; 11,890 in women)
28
. The incidence 
rate of gastric cancer was four times higher in Southern India compared with 
Northern India
29
.The rates in rural population were much lower than those in the 
urban population.  Among the six registries in Southern India, the highest 
incidence in both sexes was reported from Chennai. The age-standardized 
incidence rates in Chennai are 13.6 per 100,000 in men and 6.5 per 100,000 in 
women
28
.  
The 5 year survival rate of early gastric cancers is higher (upto 95%) 
when compared to those of advanced gastric cancer (10% -20%)
30
.  
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Clinical presentation: 
The symptoms associated with gastric cancer are usually non-specific. 
Early gastric cancers are usually asymptomatic. Some of them may cause 
anorexia, weight loss, fatigue, nausea, vomiting and mild to moderate epigastric 
distress. Hematemesis occurs in 10% to 15% cases. Proximal gastric tumours 
cause dysphagia and distal gastric tumours may cause gastric outlet obstruction. 
Pathogenesis: 
Gastric carcinogenesis is a multistep and multifactorial process that in 
many cases appears to involve a progression from normal mucosa through 
chronic gastritis, atrophic gastritis and intestinal metaplasia to dysplasia and 
carcinoma
31
. 
Risk factors: 
The risk factors associated with gastric carcinoma include  chronic 
atrophic gastritis, Helicobacter pylori infection, diets rich in salt (dried and 
salted fish) and low in micronutrients (vitamin C), intestinal metaplasia, 
smoking, pernicious anemia, bile reflux in patients with post-operative gastric 
stumps, Menetrier‟s disease and peptic ulcer disease32,33. First-degree relatives 
of affected patients are almost three times as likely to develop the disease as the 
general population. This may be partly attributable to H. pylori infection being 
commoner in families, and the potential role of IL-1 gene polymorphisms. 
6
Etiology: 
Diet: 
The most consistent etiological factor associated with gastric cancer is 
diet. Intraluminal and intramucosal synthesis of carcinogens like N- 
nitrosamines by bacteria
34 
and excessive salt which acts as an irritant
35-37
, cause 
inflammation and intestinal metaplasia which later leads to malignancy. 
Consumption of fresh fruits and vegetables which contain Vitamin C, Vitamin E 
and carotenoids
38
 counteracts the formation of N-nitroso compounds
39
 and 
scavenges oxygen free radicals, thereby playing a protective role.  
Helicobacter pylori infection: 
Several epidemiological investigations have found a consistent 
association between H.pylori seropositivity and risk of gastric cancer
40,41
. The 
development of severe gastritis with atrophy and intestinal metaplasia is 
particularly associated with infection by CagA-positive strains of the 
bacillus
42,43
 and these strains have been associated with increased risk of gastric 
cancer in some studies
44
. The sequence of events include development of 
atrophic gastritis, intestinal metaplasia, dysplasia and carcinoma. The various 
mechanisms proposed are increased epithelial cell proliferation with a resultant 
increased risk of mutations
45
, bacterial overgrowth with increased potential to 
generate intraluminal carcinogens
46
, increased free radicals
47
 and reduced 
gastric antioxidant levels
48
.  
Genetic predisposition: 
7
There is evidence that germline truncating mutations in the gene for E-
cadherin (CDH-1), a calcium-dependent cell adhesion protein, are responsible 
for a rare autosomal dominant inherited form of gastric carcinoma in young 
persons. This condition is characterized by multiple tumours of diffuse or signet 
ring cell histological types that do not arise in a background of intestinal 
metaplasia
49
. Affected family members can be identified by mutation-specific 
genetic testing and offered prophylactic gastrectomy
50
. Patients with hereditary 
non-polyposis colorectal cancer (HNPCC), which results from germline 
mutation of one of the DNA mismatch repair genes hMLH1, hMSH2, hMSH6, 
hPMS1 and hPMS2 also have an increased frequency of gastric cancers
51
. Peutz 
– Jegher‟s syndrome also shows an increased risk of gastric cancers52.    
Topography of gastric carcinoma 
Carcinomas of the distal stomach are most common in the prepyloric 
region, in the pyloric antrum and on the lesser curvature. Tumours arising at the 
cardia in the region of the oesophago-gastric junction (OGJ), whose frequency 
is increasing are generally smaller than those of the distal stomach. In 1996, 
Siewert et al proposed a classification of gastro-oesophageal junction 
adenocarcinomas based upon their location relative to the gastro-oesophageal 
junction. The tumours whose centre lay between 5 cm proximal to and 5 cm 
distal to the gastro-oesophageal junction were considered to be oesophago-
gastric junction tumours. Siewert et al subdivided these gastro-oesophageal 
junction cancers into type I if the tumour centre lay 1–5 cm proximal to the 
8
gastro-oesophageal junction, type II if between 1 cm proximal and 1 cm distal 
to the junction and type III if 1–5 cm distal to the junction53. This classification 
has been internationally recognised and is used by surgeons to plan 
management of the tumour. 
Early gastric cancer: 
Early gastric cancer is defined as a carcinoma which is limited to the 
mucosa or the mucosa and submucosa only, irrespective of the lymph node 
status. It can be subdivided further after histological examination into two 
groups, intramucosal and submucosal carcinoma. The term „early‟ does not 
imply a stage in the genesis of the cancer but means that the gastric cancer is 
potentially curable
54
. Early gastric cancer is also known as superficial spreading 
carcinoma
55
, surface carcinoma
56
 and cancer gastrique au début
57
. Increasing 
numbers of early gastric cancers are being detected mainly due to screening 
programs in countries like Japan. The mean age at presentation is somewhat 
lower
58
 and the duration of symptoms is generally longer
59
.  
Advanced gastric cancer: 
Advanced gastric cancer is defined as a carcinoma which has spread 
beyond the submucosa into the muscularis propria and beyond, irrespective of 
the lymph node status. The term „advanced‟ does not indicate a higher stage of 
disease but means that treatment of such tumours is difficult and has decreased 
survival rates. 
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Macroscopic appearance of gastric cancer: 
A sub-classification of the gross appearance of early gastric cancer was 
devised by the Japanese Gastro-enterological Endoscopic Society on the basis 
of macroscopic appearances at endoscopy and in gastrectomy specimens. They 
were divided into three main types and three subtypes. (Figure 1) 
 
Type I -  Protruded -    The tumour projects clearly into the lumen and  
                                         includes all polypoid, nodular and villous tumours. 
Type II – Superficial -  This is further subdivided into three groups: 
                     Type IIa  - Elevated above surrounding mucosa by few  
                                        millimetres.This is seen as a well – circumscribed flat  
                                        plaque.               
                      Type IIb - Flat. No abnormality is macroscopically visible 
                      Type IIc - Depressed. The surface is slightly depressed below  
                                        adjacent mucosa  
Type III – Excavated -  Ulceration of variable depth into the gastric wall. 
 
EGC is located mainly in the corpus and antrum of the stomach
60 
. 
Lesions are multifocal in up to 14% of cases
61
.   
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                          Figure 1 : Gross classification of early gastric cancer 
 
Macroscopic types of advanced gastric cancer can be understood from the 
schema depicted in 1925 by Dr. R. Borrmann, who was a German surgeon and 
pathologist. (Figure 2) 
                           Type I   –  Polypoid / Nodular 
                           Type II  – Ulcerative, localized / Fungating 
                           Type III – Ulcerative, infiltrative 
                           Type IV – Diffusely infiltrative 
                 
11
        Figure 2 : Borrmann classification of gross types of advanced gastric cancer 
 
 Ulcerated tumours occur most frequently in the antrum on the lesser 
curve and these ulcers are large with an irregular margin, raised rolled edges 
and necrotic shaggy base
62
. Polypoid, fungating and nodular tumours tend to 
occur in the body of the stomach in the region of the greater curvature, posterior 
wall or fundus.  Infiltrative cancers spread superficially in the mucosa and 
submucosa producing plaque-like lesions. It is commonly accompanied by 
thickness of the entire stomach wall producing the so-called linitis plastica or 
„leather bottle‟ stomach. Many gastric carcinomas secrete considerable amounts 
of mucin which gives the gelatinous appearance of colloid carcinomas. 
12
Gastric adenocarcinomas are either gland-forming malignancies 
composed of tubular, acinar or papillary structures, or they consist of a complex 
mixture of discohesive, isolated cells
63
. Several classification systems have been 
proposed, including Ming, Carniero, and Goseki, but the most commonly used 
are those of WHO
64
 (Annexure II) and Laurén. 
WHO CLASSIFICATION: 
Tubular adenocarcinoma : 
Tubular adenocarcinoma is composed predominantly of neoplastic 
tubules often showing irregular branching and anastomosis embedded in or 
surrounded by fibrous stroma. Individual tumour cells are columnar, cuboidal, 
or flattened by intraluminal mucin. The degree of cytological atypia varies from 
low to high-grade. A poorly differentiated variant is sometimes called solid 
carcinoma. An oncocytic variant of tubular adenocarcinoma has been 
described
65
. 
Papillary adenocarcinoma : 
These are well-differentiated carcinomas with elongated finger-like 
processes lined by cuboidal cells supported by fibro-vascular connective tissue 
cores. Some 
tumours show tubular differentiation (papillotubular). Rarely, a micropapillary 
architecture is present. Typically this tumour grows as a polypoid mass into the 
lumen of the stomach. 
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Mucinous carcinoma :  
WHO defines carcinomas containing large amounts of extracellular 
mucin in more than 50% of the tumour as Mucinous carcinomas. In some such 
tumours the cells form glands lined by columnar mucus-secreting cells (well 
differentiated type). In others there are disaggregated ribbons or clusters of cells 
which appear to be floating in lakes of mucin (poorly differentiated type). There 
may also be mucin in the inter-glandular stroma. Scattered signet-ring cells, 
when present, do not dominate the histological picture. They most commonly 
occur as polypoid, fungating or ulcerative masses. 
Signet ring cell carcinoma: 
WHO defines this tumour as “Carcinomas composed predominantly of 
single cells or small clusters of cells containing intra-cytoplasmic mucus 
vacuoles and accounting for more than 50% of the tumour”. The cells contain 
nuclei which push against cell membranes creating a classical signet ring cell 
appearance due to an expanded, globoid, optically clear cytoplasm. These 
contain acid mucin and stain with Alcian blue at pH 2.5. They also contain cells 
with no mucin and cells with eosinophilic granular cytoplasm containing neutral 
mucin. These tumours are more common in younger patients and in the distal 
stomach. Signet ring cell carcinomas tend to infiltrate the wall of the stomach 
diffusely and are accompanied by marked fibrosis giving rise to the linitis 
plastica  appearance on gross examination.  
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LAUREN CLASSIFICATION : 
The histological classification of Lauren
22 
(1965) divides gastric 
adenocarcinoma into two main types - Intestinal and Diffuse. Tumours that 
contain approximately equal quantities of intestinal and diffuse components are 
called mixed carcinomas. Carcinomas too undifferentiated to fit neatly into 
either category are placed in the indeterminate category. 
Intestinal carcinoma: 
 Intestinal-type tumours have a glandular pattern usually accompanied by 
tubules papillary formation or solid components. The glands range from well 
differentiated to moderately differentiated grade, sometimes with poorly 
differentiated tumour at the advancing margin. The glandular epithelium 
consists of large pleomorphic cells with large hyperchromatic nuclei often with 
numerous mitoses. The adjacent gastric mucosa often shows chronic gastritis, 
widespread intestinal metaplasia and sometimes dysplasia. Intestinal-type 
tumours are commoner in the elderly and in males. 
Diffuse carcinoma: 
Diffuse-type carcinomas are predominantly composed of poorly cohesive 
diffusely infiltrating small tumour cells with indistinct cytoplasm and 
hyperchromatic nuclei. Glandular formation may occur in the more superficial 
part of the tumour. Signet ring cells are common and there may be extracellular 
mucin in the stroma. Desmoplasia is more pronounced and generally there is no 
15
accompanying intestinal metaplasia or dysplasia. The diffuse tumours usually 
occur at a younger age and there is equal sex incidence. 
 CLASSIFICATION OF MING :  
The Ming‟s classification (1977) divides gastric adenocarcinomas into 
two types - Expanding type and Infiltrating
23
. The expanding type has a pushing 
edge and forms discrete tumour nodules. This compares roughly to the intestinal 
type of Lauren and occurs in patients over 50 years of age. The infiltrative type 
is ill defined and contains widely infiltrative tumour cells with poor 
inflammatory cell response and collagenous stroma and is more common under 
the age of 50. 
CLASSIFICATION OF MULLIGAN AND REMBER :  
This classification expands Lauren‟s classification by adding a third type 
- pylorocardiac gland carcinoma
66
.  Pylorocardiac carcinomas commonly 
present as well demarcated fungating tumours. These tumours are commoner in 
men and are characterized microscopically by varying-sized glands showing 
tubular or papillary pattern cells that often show striking vacuolation or clear 
cell change and stain brilliantly with the periodic acid–Schiff  reaction. 
THE GOSEKI CLASSIFICATION : 
Goseki et al divided gastric cancer into four histological types according 
to the degree of tubular differentiation and the amount of intracellular mucin
67
. 
Group I - consists of well differentiated tubules with poor intracellular mucin.  
Group II - consists of well differentiated tubules & plentiful intracellular mucin. 
16
Group III – consists of poorly differentiated tubules & poor intracellular mucin; 
Group IV - consists of poorly differentiated tubules & plentiful intracellular  
                    mucin. 
CARNEIRO CLASSIFICATION : 
Carneiro et al proposed a much simpler system in which the tumours are 
divided into glandular, isolated cell carcinomas, solid variety and a mixed type 
that consists of a mixture of glandular and isolated cell types
63
.  
The rare variants of gastric carcinoma include Adenosquamous 
carcinoma
68
, Squamous cell carcinoma
69
, Hepatoid adenocarcinoma
70
, 
Choriocarcinoma
71
, Medullary carcinoma with lymphoid stroma
72
, Small cell 
carcinoma
73
, Parietal cell carcinoma
74
, Gastric carcinoma with rhabdoid 
features
75
 and Carcinosarcoma
76
.  
SPREAD OF GASTRIC CANCER 
Gastric cancer may spread directly through penetration of the serosa and 
infiltration into organs like pancreas, liver, spleen, transverse colon and 
omentum and this is particularly common in signet ring cell carcinomas and 
diffuse carcinomas. The incidence of lymphatic spread increases with increasing 
depth of invasion into the stomach wall. The nodes commonly involved include 
the nodes along the left gastric, common hepatic, coeliac arteries and the 
pancreatic and splenic nodes. More distant lymphatic spread may involve para-
aortic and mesenteric nodes. Spread by way of the thoracic duct to the left 
supraclavicular nodes (nodes of Troisier and of Virchow) is not common. 
17
Hematogenous spread occurs most commonly to the liver, followed by lung, 
peritoneum, adrenal glands, skin and ovaries (Krukenberg tumour). Diffuse 
tumours tend to involve unusual sites such as kidney, spleen, uterus and 
meninges more often
77
.  
STAGING OF GASTRIC CANCER : 
The TNM staging system
78
 (Annexure III) is widely used in western 
countries. It is the best available predictor of prognosis and is recommended. 
PROGNOSIS: 
The prognosis of gastric carcinoma varies from country to country with 
Japan having the best results with an overall 5-year survival rate of 46% for 
advanced carcinoma and 89% for early carcinoma
79
.  The overall survival rate 
in the Western countries is between 4% and 13%
80
. This can be explained at 
least partly by the greater frequency of superficial carcinomas, aggressive 
Japanese surgical approach to treatment with extensive and meticulous lymph 
node dissection
81
. A recent study of untreated early gastric cancer has indicated 
a 63% cumulative 5-year risk of progression to advanced cancer
82
.  
PROGNOSTIC FACTORS: 
Prognostic factor is defined as any variable that provides information 
useful in assessing the outcome at the time of diagnosis of the disease. The 
prognostic factors are classified as clinical factors, morphological factors and 
genetic / molecular factors. The clinical factors with poor prognosis include 
younger age group, larger tumor size, and proximal gastric cancers
80
. The 5-
18
year survival rates in tumours of the cardia are under 20%
83 
and the median 
survival is about 7 months only
84
. The pathological factors play a more useful 
role in assessing prognosis which includes the following: 
 
1. Tumour stage: This parameter is the most significant prognostic 
factor. One of the features that it incorporates is the depth of the 
invasion, for the deeper the penetration, the greater the chance of 
metastasis. This feature is directly related to the gross appearance of 
tumour – large intraluminal neoplasms have lower incidence of 
metastasis than those growing primarily within the wall. 
2. Microscopic type and grading: The intestinal type tumours in 
Lauren‟s classification behave relatively better than the diffuse 
types
85
.  
3. Regional lymph node involvement: With nodal involvement the 5-
year survival rate drops to less than 10% when compared to 50% in 
the node negative cases. The number of nodes involved is also 
prognostically significant. The overall survival rate declines as the 
number of positive node increases
86
. 
4. Tumour size: Small tumour size is associated with a better prognosis 
but this is closely linked to the depth of penetration
79
. 
5. Perineural invasion is associated with poor prognosis when 
compared to the negative cases. 
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6. Lymphatic invasion is a poor prognostic factor strongly associated 
with the presence of lymph node metastasis and poor patient survival. 
7. Vascular invasion denotes the infiltration of tumor cells into vascular 
spaces and it predicts the risk of recurrence and visceral metastasis. 
Other factors reported to have poor prognosis includes tumour necrosis, 
infiltrative tumour margins and positive surgical margins. 
Many molecular biomarkers have been identified which play a significant 
prognostic role in gastric carcinoma management. DNA aneuploidy has been 
reported in approximately 40–50% of gastric carcinomas and it has been found 
that aneuploid tumours are significantly associated with both lymph node and 
distant metastases and lower survival rates in comparison with diploid cancers
87
.  
Her 2 neu is a transmembrane epidermal growth factor receptor protein also 
known as c erb2. Its overexpression is reported to have poorer outcome
88
. 
Mutation of the p53 gene was identified in approximately 25% of gastric 
carcinomas and this correlated well with demonstration of p53 protein 
overexpression by immunohistochemistry in these tumours. Some studies based 
on immunohistochemistry indicate that p53 protein overexpression is associated 
with shortened survival
89
 but some studies failed to confirm this
90
. E-cadherin is 
a transmembrane protein which plays an important role in maintenance of 
intercellular connections. Germline mutations of the E-cadherin gene (CDH-1) 
are associated with cancers of diffuse type and are highly aggressive
91
. Other 
factors like increased expression of cathepsin D, p27kip1, increased 
20
proliferation indices and loss of Fhit protein are associated with reduced 
survival. 
p53 : 
p53 was identified in 1979 by Lionel Crawford, David P. Lane, Arnold 
Levine, and Lloyd Old. The human TP53 gene was cloned in 1985. Its character 
as a tumor suppressor gene was revealed in 1989 by Bert Vogelstein. p53 gene 
is considered “Guardian of the genome” and represents a tumor suppressor gene 
located on the 17p chromosome, coding a protein of 53 kD. The role of p53 is 
central in cell – cycle regulation, in DNA repair and in cell apoptosis. The 
production of p53 is increased in response to cellular insults or DNA damage 
and p53 then induces cell - cycle arrest at the G1/S junction. Therefore, p53 is 
essential for control of tumor growth, apoptosis and maintaining genome 
stability.  Unlike normal p53 protein, which is rapidly removed from the 
nucleus, mutant forms have a prolonged half-life, which favors intranuclear 
accumulation, becoming detectable immuno-histochemically.  Mutations of the 
p53 have been observed in a wide variety of human carcinomas, such as 
colorectal carcinoma, breast carcinoma, gallbladder carcinoma, esophageal 
carcinoma, and gastric carcinoma. Numerous studies have reported the 
correlation between the overexpression of p53 and the poor prognosis of 
patients with these tumors. The p53 pathway is also involved in regulating the 
metastasis-associated genes, including Maspin, integrin, matrix metallo-
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proteinase-2 (MMP-2), MMP-13 and the tissue inhibitor of metalloproteinase-3 
(TIMP3). 
Mutation of the p53 gene was identified in approximately 25% of gastric 
carcinomas and this correlated well with demonstration of p53 protein 
overexpression by immuno-histochemistry in these tumours. Carcinomas of the 
cardia showed mutation of p53 in a considerably higher proportion of cases than 
carcinoma of the body or antrum
96
. Overall prevalence of p53 immunoreactivity 
in advanced gastric carcinoma is about 50–60%. Alterations of the p53 gene 
have also been demonstrated in precancerous lesions of the stomach. The p53 
gene mutation and overexpression of gene protein is more common in 
intestinal-type carcinomas than in diffuse tumours
97
. Some studies based on 
immuno -histochemistry indicate that p53 protein overexpression is associated 
with shortened survival but few other studies have failed to confirm this
89,90
. 
The most commonly used methods for detection of these mutations are 
immunohistochemistry, flow-cytometry, polymerase chain reaction-single-
strand conformation polymorphism (PCR – SSCP) and genomic sequencing. 
Although sequencing is the most unambiguous method, it is technically 
cumbersome. Therefore, both immune-detection and PCR- SSCP have been 
widely used as alternative methods. 
Immuno-histochemically, a positive reaction is considered in the presence 
of brown immunostained nuclei.  
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 p53-negative (-): Absence of immunostaining in < 10% of the tumour nuclei  
p53-positive (+): Presence of immunostaining in > 10% of the tumour  nuclei  
Ki-67: 
 Ki-67 also known as MKI67 is a protein encoded by the MKI67 gene
98 
which was discovered by Gerdes. The Ki-67 protein was originally defined by 
the prototype monoclonal antibody Ki-67, which was generated by immunizing 
mice with nuclei of the Hodgkin lymphoma cell line L428. The name is derived 
from the city of origin (Kiel, Germany) and the number of the original clone in 
the 96-well plate. 
Ki-67 is a nuclear protein that is necessary for cellular proliferation and 
ribosomal RNA transcription
99
. It is present during all active phases of the cell 
cycle (G1, S, G2, and M), but is absent from resting cells (G0). The protein is 
predominantly localized in the peri-nucleolar region in the G 1 phase, in the 
later phases it is also detected throughout the nuclear interior, being 
predominantly localized in the nuclear matrix. In mitosis, it is present on all 
chromosomes
98
. Ki-67 is an excellent marker to determine the growth fraction 
of a given cell population. The fraction of Ki-67-positive tumor cells (the Ki-67 
labeling index) is often correlated with the clinical course of various tumours 
like carcinomas of the prostate, brain and the breast. For these types of tumors, 
the prognostic values for survival and tumor recurrence have repeatedly been 
proven in uni- and multivariate analysis.  
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MIB-1 is a commonly used monoclonal antibody that detects the Ki-67 
antigen. It is used in clinical applications to determine the Ki-67 labeling index. 
One of its primary advantages over the original Ki-67 antibody and the reason 
why it has essentially replaced the original antibody for clinical use is that it can 
be used on formalin-fixed paraffin-embedded sections, after heat-mediated 
antigen retrieval. Ki-67 labeling index is calculated by the percentage of 
tumours cells showing distinct brown staining of the nucleus with strong 
intratumoural heterogeneity. The other methods of detection of Ki-67 are by 
Western blot analysis and immunofluorescence.  
The various other markers of proliferation include AgNOR staining, 
PCNA and Topoisomerase II. The novel markers being evaluated for 
identifying cell proliferation include Fen-1, MCM proteins (mini-chromosome 
maintenance), mitosin, polo – like kinase and claspin.  
IMMUNOHISTOCHEMISTRY: 
Albert Coons et al in 1941 first labeled antibodies directly with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, introduced indirect 
labeling technique in which unlabeled antibody is followed by second antibody 
or substrate. Various stages of development of Immunohistochemistry include 
peroxidase – antiperoxidase method (1970), alkaline phosphatase labeling 
(1971), avidin biotin method (1977) and two layer dextrin polymer technique 
(1993)
92
. 
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 ANTIGEN RETRIEVAL:  
Antigen retrieval can be done by the following different techniques to 
unmask the antigenic determinants of fixed tissue sections. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
PROTEOLYTIC ENZYME DIGESTION: 
Huank et al in 1976 introduced this technique to breakdown formalin 
cross linkages and to unmask the antigen determinants. The most commonly 
used enzymes include trypsin and proteinase
93
. The disadvantages include over 
digestion, under digestion and antigen destruction. 
MICROWAVE ANTIGEN RETRIEVAL: 
This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections in 
various buffers for rapid and uniform heating. Antibodies against Ki67 and 
MIB-1 work well after heat pretreatment in this method
92
. 
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PRESSURE COOKER ANTIGEN RETRIEVAL: 
Miller et al in 1995 compared and proved that pressure cooking method has 
fewer inconsistencies, less time consuming and can be used to retrieve large 
number of slides than in microwave method
94
.
 
PITFALLS OF HEAT PRETREATMENT: 
Drying of sections at any stage after heat pretreatment destroys 
antigenicity. Nuclear details are damaged in poorly fixed tissues. Fibers and 
fatty tissues tend to detach from slides while heating. Not all antigens are 
retrieved by heat pretreatment and also some antigens like PGP 9.5 show altered 
staining pattern. 
DETECTION SYSTEMS: 
After addition of specific antibodies to the antigens, next step is to 
visualize the antigen antibody reaction complex. The methods employed are 
direct and indirect methods.  
In the direct method, primary antibody is directly conjugated with the 
label. Most commonly used labels are flouro-chrome, horse radish peroxidase 
and alkaline phosphatase. Indirect method is a two-step method in which 
labeled secondary antibody reacts with primary antibody bound to specific 
antigen. The use of peroxidase enzyme complex or avidin biotin complex 
further increases the sensitivity of immunohistochemical stains
92
.
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In 1993, Pluzek et al introduced enhanced polymer one step staining, in 
which large numbers of primary antibody and peroxidase enzymes are attached 
to dextran polymer back bone. This is the rapid and sensitive method
95
. 
Dextran polymer conjugate two step visualization system is based on 
dextran technology in Epos system. This method has greater sensitivity and is 
less time consuming. 
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MATERIALS AND METHODS 
 
This study is a retrospective descriptive study of gastric adenocarcinomas 
conducted in the Institute of Pathology, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai during the period between 
January 2010 and December 2010.  
A total of  9,541 cases were submitted to our department during the 
period January 2010 – December 2010 for histopathological examination. 
Among the 660 gastric specimens, 571 were endoscopic biopsies and 89 were 
gastrectomies. Among the 660 specimens, 297 were non neoplastic, 4 were 
benign and 359 were malignant tumours. A total of 275 endoscopic biopsy 
specimen and 84 gastrectomy specimens were reported to be malignant tumors. 
Out of the 89 gastrectomies, 78 gastrectomies were done to treat gastric 
carcinoma, 3 were done to treat GIST, 3 were done to treat Non – Hodgkin‟s 
lymphoma, 3 were done to treat giant bleeding benign ulcers, 1 was done to 
treat morbid obesity and 1 was done as revision gastrectomy to rule out stump 
carcinoma. 
SOURCE OF DATA: 
The gastric adenocarcinoma cases reported in gastrectomy specimens 
received in the Institute of Pathology, Madras Medical College between January 
2010 to December 2010 from the Department of Surgery, Surgical 
Gastroenterology, Surgical Oncology and Geriatric surgery, Government 
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General Hospital. A total of 84 gastrectomy specimens (Subtotal, Total, Radical 
and Palliative gastrectomy) were received during this period.  
Inclusion criteria 
All the gastric carcinoma cases reported in gastrectomy specimens 
irrespective of the age and sex were included for the study. 
Exclusion criteria 
 Non neoplastic lesions and benign tumors of stomach. 
 Gastric carcinomas reported in endoscopic biopsies. 
 Gastrectomies performed for reasons other than treating carcinomas. 
METHOD OF DATA COLLECTION: 
 Detailed history of the cases regarding age, sex, history, type of 
procedure, history of neo adjuvant therapy, details of gross characteristics and 
nodal status were obtained for all the 78 gastrectomy cases reported during the 
period of study from Surgical pathology records. Hematoxylin and Eosin 
stained 4 µ thick sections of the paraffin tissue blocks of gastrectomy specimens 
were reviewed. The following clinical and pathological parameters were 
evaluated: Age (<55 and >= 55), gender, tumour size (<5 and >=5cm), tumour 
location (Eso-cardiac, body, antrum, pangastric), macroscopic appearance 
(Borrmann Type I, Type II, Type III and Type IV). Carcinomas were classified 
as Intestinal and Diffuse based on the Lauren classification and into different 
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histological types (tubular, papillary, mucinous, signet ring cell and diffuse). 
Regarding the depth of invasion, the carcinomas were classified into 4 groups: 
T1 (invasion of mucosa and submucosa), T2 (invasion of muscularis propria 
and subserosa), T3 (invasion of serosa) and T4 (invasion of adjacent organs), 
and according to grade the carcinomas were divided into 3 groups: G1 (well 
differentiated), G2 (moderately differentiated) and G3 (poorly differentiated) 
according to the recommendations of the American Joint Committee on Cancer 
(2002). Lymph node metastasis was assessed and the patients were divided into 
3 groups: N0 (No lymph node metastasis), N1 (metastasis in 1-6 nodes) and N2 
(metastasis in 7 – 15 nodes). Carcinoma staging was done according to the 
standards of the American Joint Committee on Cancer (2002) and TNM 
classification of gastric carcinomas (Annexure – III). The tumours were further 
evaluated for the presence of necrosis, lymphocytic response, perineural 
invasion and lympho-vascular invasion by tumor and were graded as present or 
absent. 50 cases of gastric adenocarcinomas of varying grades were randomly 
selected from the total cases and their representative formalin fixed paraffin 
embedded tissue samples were subjected to immunohistochemistry for a panel 
of 2 markers – p53 and Ki-67. 
IMMUNOHISTOCHEMICAL EVALUATION: 
Immuohistochemical analysis of a panel of markers including p53 and 
Ki-67 were done in paraffin embedded tissue samples using Super-sensitive 
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polymer HRP system based on non-biotin polymeric technology. 4 µ thick 
sections from formalin fixed paraffin embedded tissue samples were transferred 
onto gelatin coated slides. Heat induced antigen retrieval was done. The antigen 
was bound with mouse monoclonal antibody (Biogenex) against p53 protein 
and Ki – 67 protein and then detected by the addition of secondary antibody 
conjugated with horse radish peroxidase-polymer and diaminobenzidine 
substrate. The step by step procedure of Immunohistochemistry is given in 
Annexure IV. 
Antigen Vendor Species(clone) Dilution Positive control 
P53 BIOGENEX Mouse Ready to use Stomach 
Ki - 67 BIOGENEX Mouse Ready to use Stomach 
 
INTERPRETATION & SCORING SYSTEM: 
The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization, percentage of cells stained and 
intensity of reaction. Nuclear staining was assessed for both p53 and Ki 67. P53 
immuno-reactivity was assessed as being positive when tumours exhibited 
intense nuclear staining and was categorized into 2 groups: Positive expression - 
(at least 10% positive tumour cell nuclei) and  Negative expression - (less than 
10% positive tumour cell nuclei) 
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A distinct nuclear immuno – reactivity for Ki -67 was considered 
positive. The Ki-67 labeling index was determined by observing 1000 cancer 
cell nuclei in areas of the section with highest labeling frequency. The Ki- 67 
labeling index for the 50 tumours ranged from 3.9% to 75.3% with a mean 
labeling index of 25.4%. The mean Ki – 67 labeling index of 25.4% was chosen 
as the cut off point for separating the cases into 2 groups:  High Ki – 67 labeling 
index (LI > 25.4%) and Low Ki – 67 labeling index (LI < 25.4%).    
STATISTICAL ANALYSIS : 
The statistical analysis was performed using statistical package for social 
science software version 11.5 which consisted computing the frequency counts 
and percentages for qualitative variables and mean for the quantitative variables.  
The expression of p53 and the Ki – 67 labeling index was correlated with 
clinico – pathological factors like age, gender, tumour site, tumour 
configuration, size, Lauren‟s type, histological types, histological grade, depth 
of infiltration, lymph node status, stage, lympho-vascular invasion, perineural 
invasion, lymphocytic response and necrosis using the Pearson‟s Chi –Square 
test. The expression of p53 and the Ki – 67 labeling index were also correlated 
with each other using the McNemar‟s test. T – test was used to detect the 
association between the mean Ki- 67 labeling index in the p53 positive and 
negative groups. 
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OBSERVATION AND RESULTS 
In the study period of 12 months from January2010 to December 2010, a 
total of 9,541 specimens were received in the Institute of Pathology, Madras 
Medical College for histological examination. Total numbers of gastric 
specimens received were 660, of these gastric tumors accounted for 359 with a 
percentage of 3.76 %. The total number of non- neoplastic, benign and 
malignant cases was 297, 4 and 359 respectively. Thus the distribution of non-
neoplastic lesions was 45 %, of benign tumors were 0.6% and of malignant 
tumors were 54.39% among the gastric specimens.  
Among the 660 gastric specimens, there were 89 gastrectomies. Of the 89 
gastrectomies, 78 were done to treat gastric carcinoma, 3 were done to treat 
GIST, 3 were done to treat Non – Hodgkin‟s Lymphoma and the remaining 5 
for non – neoplastic conditions. Thus the distribution of non-neoplastic lesions 
was 5.7% and malignant tumours was 94.3% among the gastrectomy 
specimens. 
Gastric cancers had a peak incidence in the age group of 51-60 years. The 
youngest age of presentation of gastric cancer is at 23 years in this study. 
Among the 78 cases, 57 (73%) cases were reported in males and 21 (27%) cases 
were reported in females (Table 1 and Chart 1) 
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TABLE 1 AGE AND SEX WISE DISTRIBUTION OF GASTRIC 
CANCERS 
 
Among the 78 cases, 47 (60.3%) of cases involved the pyloro-antrum, 16 
(20.5%) involved the body, 11 (14.1%) involved the eso-cardia and 4 (5.1%) 
cases were pan-gastric. (Table 2 and Chart 2) 
TABLE 2 DISTRIBUTION OF SITE OF INVOLVEMENT IN GASTRIC 
CARCINOMA 
SITE OF GASTRIC CANCER NUMBER OF CASES PERCENTAGE 
Pyloro-antrum 47 60.3% 
Body  16 20.5% 
Eso-cardia 11 14.1% 
Pan-gastric 4 5.1% 
Total 78 100% 
 
AGE GROUP 
NUMBER OF 
CANCERS PERCENTAGE 
MALES FEMALES 
21 – 30 years 0 2 2.5% 
31 – 40 years 5 4 11.6% 
41 – 50 years 11 6 21.8% 
51 – 60 years 24 2 33.5% 
61 – 70 years 11 7 23% 
More than 70 
years 
6 0 7.6% 
Total cases 57 (73%) 21 (27%) 100% 
34
Based on the gross morphology, the gastric tumours were divided into 4 
groups according to Borrmann‟s classification & the distribution is shown in 
Table 3 & Chart 3 
    TABLE 3 DISTRIBUTION OF GASTRIC CARCINOMA ACCORDING 
TO     GROSS MORPHOLOGY 
GROSS NUMBER OF CASES PERCENTAGE 
Borrmann Type -  I 12 15.3% 
Borrmann Type - II 32 41% 
Borrmann Type - III 25 32% 
Borrmann Type - IV 8 10.2% 
Early gastric cancer – Type III 1 1.2% 
Total 78 100% 
 
Among the study samples, 46 cases (58.9%) had tumor less than 5 cm in 
size and 32 cases (41%) were 5cm or more in size. (Table 4 & Chart 4) 
TABLE 4 - DISTRIBUTION OF SIZE IN GASTRIC CARCINOMA 
SIZE OF TUMOUR NUMBER OF CASES PERCENTAGE 
<5 cm 46 58.9% 
>=5 cm 32 41.1% 
Total 78 100% 
 
The distribution of histological subtypes of  gastric carcinoma is shown in 
Table 5 & Chart 5. 
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TABLE 5 DISTRIBUTIONS OF HISTOLOGICAL SUBTYPES OF 
GASTRIC CANCERS 
Histological subtypes Number of cases Percentage 
Tubular carcinoma 42 53.9% 
Papillary carcinoma 5 6.5% 
Mucinous carcinoma 11 14.2% 
Signet ring cell carcinoma 6 7.6% 
Diffuse carcinoma 13 16.6% 
Squamous cell carcinoma 1 1.2% 
Total number of cases 78 100% 
 
77 of the gastric adenocarcinomas were grouped into 2 according to 
Lauren‟s classification out of which 58 (75.4%) belonged to Intestinal type and 
19 (24.6%) belonged to Diffuse type (Table 6 and Chart 6). 
TABLE 6 DISTRIBUTION OF GASTRIC CANCER ACCORDING TO 
LAUREN’S CLASSIFICATION 
LAUREN‟S  TYPE NUMBER OF CASES PERCENTAGE 
Intestinal type 58 75.4% 
Diffuse type 19 24.6% 
Total 77 100% 
 
The gastric carcinomas were graded according to AJCC recommendation 
and were divided into 3 groups, out of which 11 cases (14.2%) were well 
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differentiated (G1), 38 cases (48.7%) were moderately differentiated (G2) and 
29 cases (37.1%) were in poorly differentiated (G3). (Table 7 & Chart 7) 
TABLE 7 DISTRIBUTION OF HISTOLOGICAL GRADE IN GASTRIC 
CARCINOMAS 
GRADE NUMBER OF CASES PERCENTAGE 
G1 11 14.2% 
G2 38 48.7% 
G3 29 37.1% 
TOTAL 78 100% 
 
In this study, 1 case (1.2%) showed invasion upto the submucosa (T1), 36 
cases (46.2%) showed infiltration into the muscularis propria or subserosa (T2), 
36 cases (46.2%) showed infiltration into the serosa and 5 cases (6.4%) showed 
infiltration of adjacent organs (T4) (Table 8 and Chart 8). 
TABLE 8 DISTRIBUTION OF GASTRIC CARCINOMAS ACCORDING 
TO DEPTH OF INVASION 
DEPTH OF 
INVASION 
NUMBER OF 
CASES 
PERCENTAGE 
T1 1 1.2% 
T2 36 46.2% 
T3 36 46.2% 
T4 5 6.4% 
Total 78 100% 
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This study showed that 39 cases (50%) had up to 6 nodes with metastatic 
carcinomatous deposit (N1), 5 cases (6.4%) had 7 to 15 involved nodes (N2) 
while 34 cases (43.6%) had no  node involvement (N0). (Table 9 & Chart 9) 
TABLE 9 DISTRIBUTION OF LYMPH NODE METASTASIS IN 
GASTRIC CANCERS 
Lymph node 
status 
Number of cases Percentage 
N0 34 43.6% 
N1 39 50% 
N2 5 6.4% 
Total 78 100% 
 
In the present study, 17 cases (21.8%) belonged to stage I, 35 cases 
(44.9%) belonged to stage II, 21 cases (26.9%) belonged to stage III and 5 cases 
(6.4%) belonged to stage IV. (Table 10 and Chart 10) 
TABLE 10 DISTRIBUTION OF GASTRIC CARCINOMAS 
ACCORDING TO STAGE 
STAGE 
NUMBER OF 
CASES 
PERCENTAGE 
I 17 21.8% 
II 35 44.9% 
III 21 26.9% 
IV 5 6.4% 
Total 78 100% 
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In this study, among the 78 cases, 52 cases (66.6%) had lymphatic 
invasion as against 26 cases (33.4%) without lymphatic invasion. 15 cases 
(19.3%) showed vascular invasion while 63 cases (80.7%) cases had no 
vascular invasion, 17.9 % of the cases had perineural infiltration, 85.8% of the 
cases had lymphocytic infiltration , 23.1% of the cases had necrosis. (Table 11 
& Chart 11) 
TABLE 11 DISTRIBUTION OF OTHER PROGNOSTIC FACTORS IN 
GASTRIC CARCINOMA  
Patient characteristics Present Absent Total 
Lymphatic invasion 52 (66.6%) 26 (33.4%) 78 (100%) 
Vascular invasion 15 (19.3%) 63 (80.7%) 78 (100%) 
Perineural infiltration 14 (17.9%) 64 (82.1%) 78 (100%) 
Lymphocytic infiltration 67 (85.8%) 11 (14.2%) 78 (100%) 
Necrosis 18 (23%) 60 (77%) 78 (100%) 
 
RESULTS OF IMMUNOHISTOCHEMICAL STUDIES 
Of the total 78 cases, 50 cases of varying grade and stage were selected in 
a random manner and subjected to immunohistochemical analysis with a panel 
of 2 markers – p53 and Ki-67. 
Of the 50 cases, there were 39 males (78%) and 11 females (22%). The 
ages ranged between 28 and 75 with a mean of 55.04. There were 18 cases 
(36%) below 55 years of age and 32 cases (64%) more than 55 years. The 
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tumour was located in the pyloro – antrum in 27 cases (54%), body in 12 cases 
(24%), eso-cardia in 7 cases (14%) and were pan-gastric in 4 cases (8%). 10 
cases (20%) belonged to Borrmann Type I, 20 cases (40%) belonged to Type II, 
14 cases (28%) belonged to Type III and 6 cases (12%) belonged to type IV. 
The tumours ranged in size from 2 to 12 cm with an average of 5.72.  
There were 27 cases (54%) with tumour size <5 cm and 23 cases (46%) with 
size >5cm. 31 cases (62%) were of the tubular type, 4 cases (8%) were of the 
papillary type, 6 cases (12%) were mucinous carcinomas, 3 cases (6%) were of 
the signet ring cell type and 6 cases (12%) were of the diffuse type.  41 cases 
(82%) belonged to Lauren‟s Intestinal type and 9 cases (18%) belonged to the 
Diffuse type.  
Among the final study group, 9 (18%) cases were of G1, 25 (50%) cases 
were of G2 and 16 (32%) cases were of G3. 23 (46%) cases belonged to T2, 24 
(48%) cases belonged to T3 and 3 cases (6%) belonged to T4. Of the 50 cases, 
35(70%) showed lymphatic invasion, 13 cases (26%) showed vascular invasion, 
10 cases (20%) showed perineural invasion, 46 (92%) cases showed 
lymphocytic response and 17(34%) showed necrosis. Nodal metastasis was 
present in 1-6 nodes (N1)  in 23 cases (46%), 7-15 nodes (N2) in 5 cases (10%) 
and absent in 22 (44%) cases. 12 (24%) cases belonged to stage I, 19 (38%) 
cases belonged to stage II, 16 cases (32%) belonged to stage III and 3 cases 
(6%) belonged to stage IV. (Table 12) 
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TABLE 12 - DISTRIBUTION OF GASTRIC CARCINOMA AMONG 
THE VARIOUS CLINICOPATHOLOGICAL GROUPS FOR THE IHC 
STUDY (50 CASES) 
Clinico-pathological factor No. of cases 
 
Age 
<55 18 (36%) 
>55 32 (64%) 
 
Sex 
Males 39 (78%) 
Females 11 (22%) 
 
 
Site 
Pyloro -antrum 27 (54%) 
Body 12 (24%) 
Eso- cardia 7 (14%) 
Pan - gastric 4 (8%) 
Borrmann I 10 (20%) 
 II 20 (40%) 
 III 14 (28%) 
 IV 6 (12%) 
Size <5cm 27 (54%) 
>5cm 23 (46%) 
 
 
Histological type 
Tubular 31 (62%) 
Papillary 4 (8%) 
Mucinous 6 (12%) 
Signet ring cell 3 (6%) 
Diffuse 6 (12%) 
Lauren Intestinal 41 (82%) 
Diffuse 9 (18%) 
Grade G1 9 (18%) 
 G2 25 (50%) 
 G3 16 (32%) 
Depth T2 23 (46%) 
 T3 24 (48%) 
 T4 3 (6%) 
Lymphatic invasion P/A 35 (70%) / 15 (30%) 
Vascular invasion P/A 13 (26%) / 37 (74%) 
Perineural invasion P/A 10 (20%) / 40 (80%) 
Lymphocytic response P/A 46 (92%) / 4 (8%) 
Necrosis P/A 17(34%) / 33 (66%) 
Lymph nodes N0 22 (44%) 
 N1 23 (46%) 
 N2 5 (10%) 
Stage I 12(24%) 
 II 19 (38%) 
 III 16 (32%) 
 IV 3 (6%) 
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 In this study, 32 cases (64%) expressed positive reaction for p53 and 18 
cases (36%) were p53 negative. With the mean Ki-67 as 25.4%, the cases were 
divided into two groups – High Ki-67 labeling index which was present in 19 
cases (38%) and Low Ki-67 labeling index which was present in 31 cases 
(62%).  (Table 13 & Chart 12) 
TABLE 13 - DISTRIBUTION OF p53 EXPRESSION AND Ki -67 LI IN 
GASTRIC CARCINOMA  
IHC PARAMETER P53 Ki-67 LI 
RESULT POSITIVE NEGATIVE HIGH LOW 
 32 (64%) 18 (36%) 19 (38%) 31(62%) 
TOTAL(%) 50 (100%) 50 (100%) 
 
CORRELATION OF p53 WITH VARIOUS CLINICOPATHOLOGICAL 
FACTORS 
p53 positivity was noted in 50% patients with age less than 55 and in 
71.9% patients with age more than 55. (Table 14 & Chart 13) 
TABLE 14 CORRELATION OF AGE WITH p53 EXPRESSION 
Age (yrs) p53 positive (%) p53 negative (%) Total 
Pearson chi square 
test 
<55 9(50%) 9(50%) 18(100%) 
          P=0.215 
>55 23(71.9%) 9(28.1%) 32 (100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
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 p53 positivity was obtained  in 66.7% of men and 54.5% of women, 
noting a slight predominance in males. (Table 15 & Chart 14) 
TABLE 15 CORRELATION OF GENDER WITH p53 EXPRESSION 
Gender p53 positive (%) p53 negative (%) Total Pearson chi square test 
Male 26(66.7%) 13(33.3%) 39(100%) 
       P=0.701 
Female 6(54.5%) 5(45.5%) 11(100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
In the present study, p53 positivity was observed in 74.1% of tumours of 
the pyloro – antrum, 66.7% of tumours of the body, 14.3% of tumours of the 
eso – cardia and 75% of pan – gastric tumours. The association with respect to 
site was found to be significant with increased expression seen in tumours of the 
pyloro – antrum and in pan – gastric tumours. (Table 16 and Chart15) 
TABLE 16 CORRELATION OF TUMOUR SITE WITH p53 
EXPRESSION 
Site p53 positive (%) p53 negative (%) Total 
Pearson chi square 
test 
P - antrum 20(74.1%) 7(25.9%) 27(100%) 
       P=0.030 
Body 8(66.7%) 4(33.3%) 12(100%) 
Eso – cardia 1(14.3%) 6 (85.7%) 7 (100%) 
Pan - gastric 3 (75%) 1 (25%) 4 (100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
Among the various gross types, p53 positivity was noted in 6 cases (60%) 
of Borrmann type I, 11 cases (55%) of Borrmann type II, 10 cases (71.4%) of 
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Borrmann type III and 5 cases (83.3%) of Borrmann type IV. (Table 17 and 
Chart16) 
TABLE 17 CORRELATION OF GROSS TYPE WITH p53 EXPRESSION 
Gross p53 positive (%) p53 negative (%) Total Pearson chi square test 
Type I 6(60%) 4(40%) 10(100%) 
       P=0.555 
Type II 11(55%) 9(45%) 20(100%) 
Type III 10(71.4%) 4 (28.6%) 14 (100%) 
Type IV 5 (83.3%) 1 (16.7%) 6 (100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
In the present study, p53 positivity was noted in an increased frequency 
(70.4%) in cases with tumour size <5cm compared to the 56.5% of cases with 
size >=5cm. (Table 18 and Chart 17) 
TABLE 18 CORRELATION OF TUMOUR SIZE WITH p53 
EXPRESSION 
Size p53 positive (%) p53 negative (%) Total Pearson chi square test 
<5 cm 19(70.4%) 8(29.6%) 27(100%) 
       P=0.471 
>=5 cm 13(56.5%) 10(43.5%) 23(100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
Among histological forms, 64.5% of tubular carcinomas, 25% of 
papillary carcinoma, 33.3% of signet ring cell carcinomas and 66.7% of diffuse 
carcinomas showed p53 positivity. In this study, 100% of mucinous carcinomas 
showed p53 positivity. (Table 19 and Chart 18) 
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TABLE 19 CORRELATION OF HISTOLOGICAL TYPE WITH  p53 
EXPRESSION 
His.type 
p53 positive 
(%) 
p53 negative 
(%) 
Total 
Pearson chi square 
test 
Tubular 20(64.5%) 11(35.5%) 31(100%) 
       P=0.123 
Papillary 1(25%) 3(75%) 4(100%) 
Mucinous 6 (100%) 0 (0%) 6 (100%) 
Signet 1 (33.3%) 2 (66.7%) 3 (100%) 
Diffuse 4 (66.7%) 2 (33.3%) 6 (100%) 
Total 32 (64%) 18 (36%) 50(100%)   
 
When Lauren‟s classification was taken into account, a greater frequency 
of p53 positivation with Intestinal type cancers (65.8%) in comparison with 
diffuse type carcinomas (55.6%) was observed. (Table 20 and Chart 19) 
TABLE 20 CORRELATION OF LAUREN’S HISTOLOGICAL TYPE 
WITH p53 EXPRESSION 
Lauren 
type 
p53 positive 
(%) 
p53 negative 
(%) 
Total 
Pearson chi square 
test 
Intestinal 27(65.8%) 14(34.2%) 41(100%) 
       P=0.560 
Diffuse 5(55.6%) 4(44.4%) 9(100%) 
Total 32 (64%) 18 (36%) 
50 
(100%) 
 
 
An increasing percentage of cases showing p53 positivity with increasing 
tumour grade was observed. 44.4% of well differentiated tumours (G1), 64% of 
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moderately differentiated tumours (G2) and 75% of poorly differentiated 
tumours (G3) showing positivity for p53 was observed. (Table 21 and Chart 20) 
TABLE 21 CORRELATION OF TUMOUR GRADE WITH p53 
EXPRESSION 
Grade p53 positive (%) p53 negative (%) Total Pearson chi square test 
G1 4(44.4%) 5(55.6%) 9(100%) 
       P=0.311 G2 16(64%) 9(36%) 25(100%) 
G3 12 (75%) 4 (25%) 16 (100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
According to the T stage, a progressive increase in the number of p53 
positive cases from T2 to T3 was noted. p53 positivity was identified in 52.2% 
of T2 carcinomas, 75% of T3 carcinomas and 66.7% of T4 carcinomas.(Table 
22 and Chart 21) 
TABLE 22 CORRELATION OF T STAGE WITH p53 EXPRESSION 
T stage p53 positive (%) p53 negative (%) Total Pearson chi square test 
T2 12(52.2%) 11(47.8%) 23(100%) 
       P=0.264 T3 18(75%) 6(25%) 24(100%) 
T4 2 (66.7%) 1 (33.3%) 3 (100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
In this study, a progressive increase in the percentage of p53 positive 
cases with an increased N stage was observed.  p53 positivity was noticed  in 
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59.1 % of N0 cases, 60.9% of N1 cases and 100% of N2 cases.(Table 23 and 
Chart 22) 
TABLE 23 CORRELATION OF N STAGE WITH p53 EXPRESSION 
N stage p53 positive (%) p53 negative (%) Total Pearson chi square test 
N0 13(59.1%) 9(40.9%) 22(100%) 
       P=0.208 N1 14(60.9%) 9(39.1%) 23(100%) 
N2 5 (100%) 0 (0%) 5 (100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
 p53 positivity was noticed in 50% of stage I cases, 63.2% of stage II 
cases, 75% of Stage III cases but only 66.7 % of Stage IV cases. (Table 24 and 
Chart 23) 
TABLE 24 CORRELATION OF TNM STAGE WITH p53 EXPRESSION 
Stage p53 positive (%) p53 negative (%) Total Pearson chi square test 
I 6(50%) 6(50%) 12(100%) 
       P=0.505 
II 12(63.2%) 7(36.8%) 19(100%) 
III 12 (75%) 4 (25%) 16 (100%) 
IV 2 (66.7%) 1 (33.3%) 3 (100%) 
Total 32 (64%) 18 (36%) 50 (100%)  
 
In this study, a significant increase in the number of p53 positive cases in 
the presence of lymphatic invasion was observed. A higher percentage of p53 
positive cases were found in tumours having perineural infiltration, vascular 
invasion, lymphocytic response and necrosis. p53 positivity was noted in 74.3% 
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cases with lymphatic invasion, 76.9% cases with vascular invasion, 80% cases 
with perineural infiltration, 63% cases with lymphocytic response and 70.6% 
cases with necrosis. (Table 25) 
TABLE 25 CORRELATION OF p53 WITH PROGNOSTIC 
PARAMETERS 
Patient characteristics 
p53 Pearson chi-square 
test Positive  Negative  
Perineural  infiltration 
 
Present 8(80%) 2(20%) 
         P=0.239 
Absent 24(60%) 16(40%) 
Lymphatic invasion 
 
Present 26(74.3%) 9(25.7%) 
         P=0.046 
Absent 6(40%) 9(60%) 
Vascular invasion 
 
Present 10(76.9%) 3(23.1%) 
         P=0.428 
Absent 22(59.5%) 15(40.5%) 
Lymphocytic infiltration 
 
Present 29(63%) 17(37%) 
         P=0.633 
Absent 3(75%) 1(25%) 
Necrosis 
 
Present 12(70.6%) 5(29.4%) 
         P=0.700 
Absent 20(60.6%) 13(39.4%) 
 
The present study showed that there was statistically significant 
association between p53 expression and tumour location and lymphatic 
invasion. p53 over-expression was seen to increase with increasing age, grade, 
depth of infiltration, nodal stage and TNM stage. But when subjected to 
statistical analysis this association was not found to be significant. There was a  
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 slight predominance in males and intestinal type tumours. Increased p53 
expression was noted in Borrmann type III and type IV tumours.100% of 
mucinous carcinomas showed p53 positivity . 
CORRELATION OF Ki-67 LABELING INDEX WITH VARIOUS 
CLINICO – PATHOLOGICAL PARAMETERS 
With a mean Ki-67 labeling index of 25.4%, the study group was divided 
into 2 groups. 38% cases showed high Ki-67 labeling index and 62% cases 
showed low Ki- 67 labeling index. 
High Ki-67 LI was noted in 38.9% patients with age less than 55 and in 
37.5% patients with age more than 55. (Table 26 & Chart 13) 
TABLE 26 CORRELATION OF AGE WITH Ki -67 LI 
Age (yrs) High LI (%) Low LI (%) Total Pearson chi square test 
<55 7(38.9%) 11(61.1%) 18(100%) 
          P=0.923 
>55 12(37.5%) 20(62.5%) 32 (100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
High Ki-67 LI was noted in 38.5% of men and 36.4% of women, noting a 
slight predominance in males. (Table 27 & Chart 14) 
 
 
49
 TABLE 27 CORRELATION OF GENDER WITH Ki-67 LI 
Gender High LI (%) Low LI (%) Total Pearson chi square test 
Male 15(38.5%) 24(61.5%) 39(100%) 
       P=0.899 
Female 4(36.4%) 7(63.6%) 11(100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
In the present study, high Ki -67 LI was observed in 44.4% of tumours of 
the pyloro – antrum, 41.7% of tumours of the body, 28.6% of tumours of the 
eso – cardia and 0% of pan – gastric tumours. (Table 28 and Chart 15) 
TABLE 28 CORRELATION OF TUMOUR SITE WITH Ki-67 LI 
Site High LI (%) Low LI (%) Total Pearson chi square test 
P - antrum 12(44.4%) 15(55.6%) 27(100%) 
       P=0.353 
Body 5(41.7%) 7(58.3%) 12(100%) 
Eso – cardia 2(28.6%) 5 (71.4%) 7 (100%) 
Pan - gastric 0 (0%) 4 (100%) 4 (100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
Among the various gross types, high Ki-67 LI was noted in 4 cases (40%) 
of Borrmann type I, 8 cases (40%) of Bormann type II, 6 cases (42.8%) of 
Borrmann type III and 1 case (16.7%) of Borrmann type IV. (Table 29 and 
Chart 16) 
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TABLE 29 CORRELATION OF GROSS TYPE WITH Ki – 67 LI 
Gross High LI (%) Low LI (%) Total Pearson chi square test 
Type I 4(40%) 6(60%) 10(100%) 
       P=0.513 
Type II 8(40%) 12(60%) 20(100%) 
Type III 6(42.8%) 8 (57.2%) 14 (100%) 
Type IV 1(16.7%) 5 (83.3%) 6 (100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
In the present study, high Ki-67 LI was noted in 48.1% of cases with 
tumour size <5cm compared to the 26.1% of cases with size >=5cm. (Table 30 
and Chart 17) 
TABLE 30 CORRELATION OF TUMOUR SIZE WITH Ki-67 LI 
Size High LI (%) Low LI (%) Total Pearson chi square test 
<5 cm 13(48.1%) 14(51.9%) 27(100%) 
       P=0.190 
>=5 cm 6(26.1%) 17(73.9%) 23(100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
Among histological forms, 35.5% of tubular carcinomas, 25% of 
papillary carcinomas, 66.7% of mucinous carcinoma and signet ring cell 
carcinomas and 16.7% of diffuse carcinomas showed high Ki-67 LI. In this 
study, higher percentage of cases with high Ki-67 LI was noted in mucinous and 
signet ring cell carcinomas and higher percentage of cases with low Ki-67 LI 
was found in tubular and papillary carcinomas. (Table 31 and Chart 18) 
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TABLE 31 CORRELATION OF HISTOLOGICAL TYPE WITH Ki-67 LI 
His.type High LI (%) Low LI (%) Total Pearson chi square test 
Tubular 11(35.5%) 20(64.5%) 31(100%) 
       P=0.123 
Papillary 1(25%) 3(75%) 4(100%) 
Mucinous 4 (66.7%) 2 (33.3%) 6 (100%) 
Signet 2 (66.7%) 1 (33.3%) 3 (100%) 
Diffuse 1 (16.7%) 5 (83.3%) 6 (100%) 
Total 19(38%) 31 (62%) 50(100%)   
 
According with Lauren‟s classification, a slightly increased frequency of  
intestinal type cancers (39%) showing high Ki-67 LI in comparison with diffuse 
type carcinomas (33.3%) was noted.  (Table 32 and Chart 19) 
TABLE 32 CORRELATION OF LAUREN’S HISTOLOGICAL TYPE 
WITH Ki-67 LI 
Lauren type High LI (%) Low LI (%) Total Pearson chi square test 
Intestinal 16(39%) 25(61%) 41(100%) 
       P=0.614 
Diffuse 3(33.3%) 6(66.7%) 9(100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
It was observed that there was an increasing percentage of cases showing 
high   Ki-67 LI as the grade increased. 44.4% of moderately differentiated 
tumours (G2) and 43.8 % of poorly differentiated tumours (G3) showed high 
Ki-67 LI. A significant percentage (88.9%) of well differentiated tumours (G1) 
showed low Ki -67 LI. (Table 33 and Chart 20) 
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TABLE 33 CORRELATION OF TUMOUR GRADE WITH Ki- 67 LI 
Grade High LI (%) Low LI (%) Total Pearson chi square test 
G1 1(11.1%) 8(88.9%) 9(100%) 
       P=0.186 G2 11(44%) 14(56%) 25(100%) 
G3 7 (43.8%) 9 (56.2%) 16 (100%) 
Total 19(38%) 31 (62%) 50 (100%)  
 
According to the T stage, a progressive increase in the number of cases 
showing high Ki-67 LI from T2 to T3 was noted. The study identified high Ki-
67 LI in 30.4% of T2 tumours, 45.8% of T3 tumours and 33.3% of T4 tumours. 
(Table 34  and Chart 21). 
TABLE 34 CORRELATION OF T STAGE WITH Ki-67 LI 
T stage High LI (%) Low LI (%) Total Pearson chi square test 
T2 7(30.4%) 16(69.6%) 23(100%) 
       P=0.546 T3 11(45.8%) 13(54.2%) 24(100%) 
T4 1 (33.3%) 2 (66.7%) 3 (100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
A progressive increase in the percentage of cases with high Ki-67 LI with 
an increased N stage was observed. High LI was noticed in 34.8% of N1 cases 
and 60% of N2 cases. 63.6% of cases with no lymph node metastasis showed 
low LI (Table 35 and Chart 22). 
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TABLE 35 CORRELATION OF N STAGE WITH Ki-67 LI 
N stage High LI (%) Low LI (%) Total Pearson chi square test 
N0 8(36.4%) 14(63.6%) 22(100%) 
       P=0.562 N1 8(34.8%) 15(65.2%) 23(100%) 
N2 3 (60%) 2 (40%) 5 (100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
High LI was observed in 33.3% of stage I cases, 26.3% of stage II cases, 
56.2% of Stage III cases but only 33.3 % in Stage IV cases (Table 36 and Chart 
23). 
TABLE 36 CORRELATION OF TNM STAGE WITH Ki-67 LI 
Stage High LI (%) Low LI (%) Total Pearson chi square test 
I 4(33.3%) 8(66.7%) 12(100%) 
       P=0.320 
II 5(26.3%) 14(73.7%) 19(100%) 
III 9 (56.2%) 7 (43.8%) 16 (100%) 
IV 1 (33.3%) 2 (66.7%) 3 (100%) 
Total 19 (38%) 31 (62%) 50 (100%)  
 
In this study, high Ki67 Li was found in 42.9% of cases with lymphatic 
invasion, 69.2% of cases with vascular invasion, 70% of cases with perineural 
infiltration, 39.1% of cases with lymphocytic infiltration and 41.2% of cases 
with necrosis. The association between high LI and vascular invasion and 
perineural infiltration was found to be statistically significant. A higher 
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percentage of cases with high LI were found in tumours having lymphatic 
invasion, lymphocytic response and necrosis. (Table 37) 
TABLE 37 CORRELATION OF Ki-67 LI WITH PROGNOSTIC 
PARAMETERS 
Patient characteristics 
Ki-67 LI Pearson chi-square 
test High Low 
Perineural  infiltration 
 
Present 7(70%) 3(30%) 
         P=0.049 
Absent 12(30%) 28(70%) 
Lymphatic invasion 
 
Present 15(42.9%) 
20(57.1%
) 
         P=0.445 
Absent 4(26.7%) 
11(73.3%
) 
Vascular invasion 
 
Present 9(69.2%) 4(30.8%) 
         P=0.018 
Absent 10(27%) 27(73%) 
Lymphocytic infiltration 
 
Present 18(39.1%) 
28(60.9%
)          P=0.983 
Absent 1(25%) 3(75%) 
Necrosis 
 
Present 7(41.2%) 
10(58.8%
) 
         P=0.980 
Absent 
12 
(36.4%) 
21(63.6%
) 
 
The present study showed increased Ki-67 LI in Borrmann type III 
tumours, mucinous, signet ring cell and intestinal type carcinomas. A 
progressive increase in the number of cases showing high Ki-67 LI was noticed 
with increasing grade, depth of infiltration and nodal stage.  
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In this study, when high grade tumours were compared, it was found that 
the cases with nodal metastasis were positive for p53 immunoreaction but had 
low Ki-67 LI and the cases with no nodal involvement were  p53 negative with 
high Ki-67 LI. It was also observed that a few low grade tumours with no nodal 
metastasis were p53 positive and had a low Ki-67 LI. 
CORRELATION OF p53 EXPRESSION WITH KI-67 LABELING 
INDEX 
High Ki-67 labeling index was found in 43.8% of patients who showed 
p53 positivity and low Ki-67 LI was found in 72.2% of patients with p53 
negativity. Using the McNemar‟s test, the p value was found to be 0.011 which 
indicated no relation between p53 expression and Ki-67 LI. They were found to 
be independent prognostic variables with different outcomes for the various 
clinico-pathological factors. (Table 38 and Chart 24) 
TABLE 38 CORRELATION OF KI-67 LI WITH P53 EXPRESSION 
p53 
Ki – 67 labeling index 
Total McNemar‟s Test 
High Low 
Positive (%) 14(43.8%) 18(56.2%) 32 (100%) 
     P=0.011 
Negative (%) 5 (27.8%) 13 (72.2%) 18 (100%) 
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The mean Ki-67 LI value of p53 positive tumours was 29.362 and was 
significantly higher than that of p53 negative tumours. (Table 39 and Chart 25) 
TABLE 39 MEAN Ki 67 LI IN p53 POSITIVE AND NEGATIVE 
GASTRIC TUMOURS 
p53 N Mean Ki-67 LI t-test for equality of means 
Positive 32 29.362  
P = 0.038 Negative 18 18.361 
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GASTRIC ADENOCARCINOMA – BORRMANN TYPE I 
 
FIGURE 3 : Gastric adenocarcinoma (IT)  – Nodular  
 
 
GASTRIC ADENOCARCINOMA – BORRMANN TYPE I  
 
FIGURE 4 : Gastric adenocarcinoma (DT) –  Nodular  
 
7127/10 
2007/10 
GASTRIC ADENOCARCINOMA – BORRMANN TYPE II 
 
FIGURE 5: Gastric adenocarcinoma (IT) – Localised ulcer 
 
 
GASTRIC ADENOCARCINOMA –BORRMANN TYPE II 
 
FIGURE 6: Gastric adenocarcinoma (DT) –  Fungating 
5376/10 
6723/10 
GASTRIC ADENOCARCINOMA – BORRMANN TYPE III 
 
FIGURE 7 : Gastric adenocarcinoma (IT) – Ulcerative, infiltrative 
 
 
 
GASTRIC ADENOCARCINOMA – BORRMANN TYPE III 
 
FIGURE 8 : Gastric adenocarcinoma (DT) – Ulcerative, infiltrative 
8808/10 
7239/10 
GASTRIC ADENOCARCINOMA – BORRMANN TYPE IV 
 
FIGURE 9 : Gastric adenocarcinoma (DT) – Linitis Plastica 
 
 
MUCINOUS CARCINOMA 
 
FIGURE 10 : Diffuse glistening gelatinous growth 
4691/10 
3702/10 
PAPILLARY CARCINOMA 
 
FIGURE 11 : Ulcerative growth with raised edges 
 
 
 
KRUKENBERG TUMOUR 
 
FIGURE 12 : Solid grey – tan ovarian mass with surface bosselation 
638/10 
3729/10 
 GASTRIC ADENOCARCINOMA – INTESTINAL TYPE – GRADE I 
            
            FIGURE 13: IT – Well differentiated                   FIGURE 14 : Malignant epithelial cells in  
            with well formed glands (100X)                           gland formation with nuclear stratification  
            HPE – 938/10                                                          and pleomorphism. (400X)  HPE – 938/10   
 
 
 
 
 
GASTRIC ADENOCARCINOMA – INTESTINAL TYPE – GRADE II 
            
        FIGURE 15 : IT – Moderately differentiated       FIGURE 16 : Malignant epithelial cells with 
         with sheets and glandular formation (100X)         nuclear pleomorphism and intracellular                   
         HPE – 3584/10                                                           mucin. (400X) HPE – 3584/10  
 
 GASTRIC ADENOCARCINOMA – INTESTINAL TYPE – GRADE III 
            
        FIGURE 17 : IT – Poorly differentiated with         FIGURE 18 : Malignant epithelial cells in 
         malignant epithelial cells arranged in sheets.        sheets with nuclear pleomorphism  and  
         (100X) HPE - 4821/10                                               prominent nucleoli (400X) HPE – 4821/10 
 
 
 
 
GASTRIC ADENOCARCINOMA – DIFFUSE TYPE 
            
       FIGURE 19 :  Poorly cohesive cells diffusely           FIGURE 20 : Small and round poorly      
        infiltrating the gastric wall. (100X)                           cohesive cells (400X) HPE – 2456/10 
        HPE – 2456/10 
 
 TUBULAR ADENOCARCINOMA 
              
         FIGURE 21 : Numerous dilated, slit like and        FIGURE 22 : Tubules lined by cuboidal to  
         Irregularly branching tubules of varying size       columnar cells with cytological atypia 
         (100X) HPE – 2678/10                                              (400X) HPE – 2678/10 
 
 
 
 
PAPILLARY ADENOCARCINOMA 
               
         FIGURE 23 : Tumour cells in papillary                FIGURE 24 : Cells in delicate papillary  
         pattern with infiltration (100X) HPE -638/10       pattern with fibro – vascular core (400X) 
                                                                                             HPE – 638/10 
 
 
 MUCINOUS ADENOCARCINOMA 
       
FIGURE 25 : Chains and sheets of malignant         FIGURE 26 : Malignant epithelial cells with 
cells floating in extra – cellular mucin pool              pleomorphism and scattered signet ring cells 
(100X) HPE – 5315/10                                                  (400X) HPE – 5315/10     
 
 
 
 
SIGNET RING CELL ADENOCARCINOMA 
      
FIGURE 27 : Sheets of signet ring cells forming     FIGURE 28 : Sheets of malignant cells with 
>50% of the tumour. (100X) HPE – 4691/10             abundant intra-cytoplasmic mucin. (400X) 
                                                                                        HPE – 4691/10 
 
 SQUAMOUS CELL CARCINOMA 
      
FIGURE 29 : Moderately differentiated SCC          FIGURE 30 : Tumour cells resembling  
(100X) HPE – 8586/10                                                  squamous cells with intra-cellular keratin 
                                                                                        (400X) HPE – 8586/10 
 
 
 
 
INFILTRATION INTO MUSCULARIS PROPRIA 
      
 FIGURE 31: IT adenocarcinoma infiltrating        FIGURE 32: DT adenocarcinoma infiltrating 
 the muscularis proper (100X) HPE – 921/10          the muscularis proper (100X) HPE – 2456/10 
 
 OTHER PROGNOSTIC FACTORS 
      
      FIGURE 33 : Lymphatic invasion (400X)              FIGURE 34 : Vascular invasion (400X) 
      HPE – 151/10                                                             HPE  - 2130/10 
 
 
 
 
 
     
    FIGURE 35 : Perineural infiltration (100X)            FIGURE 36 : Lymphocytic infiltration  
    HPE – 6093/10                                                              (100X) HPE – 4821/10 
 
 
  
      
FIGURE 37 : Necrosis (100X) HPE – 4821/10         FIGURE 38 : Metastatic deposit in node  
                                                                                        (100X) HPE – 4983/10 
 
 
 
 
KRUKENBERG TUMOUR 
       
  FIGURE 39 : Malignant glands within the            FIGURE 40 : Malignant glands lined by  
  ovarian stroma (100X) HPE – 3729/10                  cuboidal cells showing pleomorphism (400X) 
                                                                                      HPE – 3729/10 
 
 
 p53 POSITIVE 
      
 FIGURE 41 : Gastric adenocarcinoma – IT             FIGURE 42 : Strong nuclear staining for 
 Grade I – Strong nuclear positivity for p53 in          p53 in > 90% of tumour nuclei. (400X) 
>90% of tumour nuclei. (100X) HPE – 7127/10        HPE – 7127/10  
 
 
 
 
p53 NEGATIVE 
             
       FIGURE 43 : Gastric adenocarcinoma – IT             FIGURE 44 : Very weak nuclear staining  
       Grade I – Very weak nuclear staining for p53          for p53 in < 5% tumour nuclei. (400X) 
       In < 5% tumour nuclei. (100X) HPE – 7165/10        HPE – 7165/10 
 
 
 
 p53 POSITIVE 
                
       FIGURE 45 : Gastric adenocarcinoma – DT         FIGURE 46 : Strong nuclear staining for  
- Strong nuclear staining for p53 in 80% of           p53 in 80% of tumour nuclei (400X) 
Tumour nuclei (100X) HPE – 2922/10                    HPE – 2922/10 
 
 
 
 
               
  
 
p53 NEGATIVE 
                 
       FIGURE 47 : Gastric adenocarcinoma – DT           FIGURE 48 : Very weak nuclear staining 
Very weak nuclear staining for p53 in <10%           for p53 in <10% of tumour nuclei (400X) 
 tumour nuclei. (100X) HPE – 2906/10                       HPE – 2906/10  
 
 
 HIGH Ki-67 LABELING INDEX 
                
       FIGURE 49 : Gastric adenocarcinoma – IT           FIGURE 50 : Strong nuclear staining for 
      Grade II – Strong nuclear staining for Ki-67          Ki-67 in 654/1000 tumour nuclei . Ki-67 LI –  
       in 645/1000 tumour nuclei. Ki-67 LI – 64.5%.        64.5% (400X) HPE – 8755/10 
       (100X) HPE – 8755/10                 
 
 
 
LOW Ki-67 LABELING INDEX 
                
       FIGURE 51 : Gastric adenocarcinoma – IT           FIGURE 52 : Moderate nuclear staining 
      Grade II – moderate nuclear staining for Ki-67      for Ki-67 in 105/1000 tumour nuclei.  
      in 105/1000 tumour nuclei. KI-67 LI – 10.5%          Ki-67 LI – 10.5% (400X) HPE – 3667/10 
       (100X) HPE – 3667/10 
 
 HIGH Ki-67 LABELING INDEX 
                
      
       FIGURE 53 : Gastric adenocarcinoma – DT         FIGURE 54 : Strong nuclear positivity for 
- Strong nuclear positivity for Ki-67 in                   Ki-67 in 502/1000 tumour nuclei.  
       502/1000 tumour nuclei. Ki-67 LI – 50.2%            Ki-67 LI – 50.2%. (400X) HPE- 4501/10 
       (100X) HPE – 4501/10 
 
 
 
 
 
LOW Ki-67 LABELING INDEX 
         
 
FIGURE 55 : Gastric adenocarcinoma – DT       FIGURE 56 : Weak nuclear stain for Ki-67 
- Weak nuclear stain for Ki-67 in 69/1000             in 69/1000 tumour nuclei. Ki-67 LI – 6.9% 
Tumour nuclei. Ki-67 LI – 6.9% (100X)               (400X) HPE – 2906/10 
HPE – 2906/10 
 
 
 p53 POSITIVE 
         
 
FIGURE 57 : Mucinous carcinoma – strong         FIGURE 58 : Strong nuclear positivity for 
nuclear positivity for p53 in >80% tumour            p53 in >80% tumour nuclei. (400X) 
nuclei. (100X) HPE – 399/10                                    HPE – 399/10 
 
 
 
 
 
 
 
 
 
HIGH Ki-67 LABELING INDEX 
        
 
FIGURE 59: Mucinous carcinoma – Strong        FIGURE 60 : Strong nuclear positivity for 
nuclear positivity for Ki-67 in 566/1000                Ki-67 in 566/1000 tumour nuclei. Ki67 LI 
tumour nuclei. Ki-67 LI – 56.6% (100X)               - 56.6% (400X) HPE – 399/10 
HPE – 399/10  
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DISCUSSION 
 
 
 
 
DISCUSSION 
Gastric cancer is a life threatening disease and represents a significant 
health problem worldwide. It is the second most common cancer worldwide and 
the third most common cancer in India
1
. The incidence of gastric cancer in 
Chennai is about 13.6 per lakh in men and 6.5 per lakh in women
28
. 
Many biological markers have been examined as possible tools for the 
evaluation of the biological behavior of gastric cancer in order to predict the 
clinical outcome. Among these, immunohistochemical staining of cell cycle 
regulator p53 and proliferation marker Ki-67 have been proposed to be of 
prognostic value. 
In the present study, immunohistochemical evaluation was done in 50 
cases of gastric carcinomas and an attempt was made to correlate the p53 
expression and Ki-67 labeling index with the known prognostic factors of 
gastric cancers.  
Madras Medical College being a tertiary referral centre, about 3.76% of 
gastric cancers was reported among the specimens received in the year 2010. 
Among the entire gastric specimens received for histopathological examination, 
54.39% of the cases were reported to be malignant. 
This study showed the age of gastric cancer patients ranged from 28 years 
to 75 years with the mean age of 55.04 years. The highest incidence of gastric 
cancer occurred in 51 to 60 year age group. This is in concurrence with the 
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study done by Y.E.Joo et al
100
 who observed a mean age of 58.7 years with a 
range from 28 to 79 years. In the study done by Nobuyuki Igarashi et al
101
 the 
incidence of gastric cancer in men and women was 74.1% and 25.9% 
respectively. In concurrence with the above study, a significant predominance 
of gastric cancers in men who accounted for 78% of the cases and women 
accounted for 22% was observed.  
The most common site of gastric cancer in this study is the pyloro – 
antrum (54%). This is almost similar to the study of N.E. Tzanakis et al
102
 and 
Daniela Lazar et al
103
. In their study, Tzanakis et al
102
 observed 51.6% tumours 
in the antrum and Daniela Lazar et al
103
 observed 50.8% tumours in the antrum 
(Table 40).  
TABLE 40 – COMPARISON OF DISTRIBUTION OF GASTRIC 
TUMOUR LOCATION 
Tumour 
location 
N.E.Tzanakis et 
al
102 
Daniela Lazar et 
al
103 
Czyzewska J 
et al
108 
Current 
study 
Antrum 51.6% 50.8% 60% 54% 
Body 34.4% 24.5% 20% 24% 
Eso – cardia 14% 13.1% 15.6% 14% 
Pan - gastric - 11.4% 4.4% 8% 
 
Daniela Lazar et al
103
 observed 8.2% of Borrmann type I tumours, 32.7% 
of type II tumours, 36% of type III tumours and 14.7% of type IV tumours. 
Similar results were observed  with 20% of type I tumours, 40% of type II 
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tumours, 28% of type III tumours and 12% of type IV tumours. Similar findings 
were also observed by Jurgen et al
104
. 
In this study, an average tumour size of 5 cm was observed which was 
similar to the findings observed by Y.E.Joo
100
 et al and Tzanakis et al
102
. Y.E 
Joo observed an average tumour size of 5.2 cm and Tzanakis et al
102
 observed 
an average tumour size of 5.1 cm. 
The most common histological subtype of gastric cancer in this study is 
Tubular carcinoma. This is almost similar to the study of Daniela Lazar et al
103
 
and Y.Kakeji et al
105
 (Table 41). 
TABLE 41 – COMPARISON OF DISTRIBUTION OF HISTOLOGICAL 
TYPES OF GASTRIC CARCINOMA 
Histological type Daniela  et al
103 
Kakeji et al
105 
Current study 
Tubular carcinoma 45.9% 89.5% 62% 
Papillary carcinoma 8.2% 2% 8% 
Mucinous carcinoma 13.1% 5.2% 12% 
Signet ring cell carcinoma 27.8% 3.1% 6% 
Diffuse carcinoma 4.9% - 12% 
 
The most common histological subtype (Lauren‟s) in this study was the 
Intestinal type (82%). This is similar to observations made by Casasola et al
106
 
wherein, intestinal type accounted for 81.9% and diffuse type accounted for 
18.1% (Table 42). 
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TABLE 42 – COMPARISON OF LAUREN”S HISTOLOGICAL TYPE 
Lauren‟s type Czyzewska et al108 Daniela et al103 Casasola et al106 Current study 
Intestinal type 75.5% 72.1% 81.9% 82% 
Diffuse type 24.5% 27.9% 18.1% 18% 
 
In the present study, the G2 (moderately differentiated) tumours were 
more common than the other grades of distribution. This was in concurrence 
with the study conducted by Casasola et al
106
 (Table 43). 
TABLE 43 – COMPARISON OF GRADE OF TUMOUR 
Grade Casasola et al
106 
Tzanakis et al
102 
Daniela  et al
103 
Current study 
G1 16% 5.4% 3.2% 18% 
G2 74.6% 22.6% 32.8% 50% 
G3 9.4% 69.9% 64% 32% 
 
A higher proportion of T3 tumours, closely followed by T2 tumours were 
observed in this study, similar to the studies of Giovanni de Manzoni et al
107
, 
and Y.E. Joo
100
 et al (Table 44). 
TABLE 44 – COMPARISON OF DEPTH OF TUMOUR 
Depth T1 T2 T3 T4 
Giovanni et al
107 
- 25% 66% 9% 
Y.E.Joo et al
100 
13.4% 24.3% 51.2% 11.1% 
Daniela et al
103 
6.5% 14.7% 27.8% 49.2% 
Jurgen et al
104 
16.9% 36.6% 38.6% 7.9% 
Current study - 46% 48% 6% 
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There was nodal metastasis in 56% of the cases and no nodal metastasis 
in 44% of   cases. This was similar to the study by Y.E Joo
100
 et al who 
observed nodal metastasis in 51.3% cases and no nodal metastasis in 48.7% 
cases & the study by Czyzewska J et al
108
 who observed nodal metastasis in 
55.6% and no nodal metastasis in 44.4% (Table 45).  
TABLE 45 – COMPARISON OF NODAL METASTASIS 
Nodal status N0 N1 N2 N3 
Giovanni et al
107 
21.4% 35.7% 42.9% - 
Daniela et al
103 
29.5% 26.2% 37.8% 6.5% 
Jurgen et al
104 
32.4% 22% 45.6% - 
Current study 44% 46% 10% - 
 
Most of the cases presented in stage II followed by closely followed by 
stage III in this study. This did not concur with the other studies which showed 
a predominance of stage IV tumours (Table 46) 
TABLE 46 COMPARISON OF STAGE OF GASTRIC TUMOUR 
Stage Daniela et al
103 
Y.E. Joo et  al
100 
Jurgen et al
104 
Current study 
I 13.1% 34.4% 27.2% 24% 
II 11.4% 16% 13.9% 38% 
III 31.1% 31.1% 28.1% 32% 
IV 42.6% 18.5% 30.8% 6% 
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 70% cases had lymphatic invasion which was similar to the observation 
made by Daniela Lazar et al
103
, who reported 62.3% and Ji Yoon Choi et al
109 
who reported 79.35% cases with lymphatic invasion in his study. 
Ji Yoon Choi et al
109
 conducted a study in 311 gastric cancer patients and 
reported vascular invasion in 20.65 % and necrosis in 38.1% of his study 
population. In comparison with the above mentioned study, this study showed 
vascular invasion in 26% and necrosis in 34% of the cases. 
There were lymphocytic infiltration in 92% and perineural infiltration in 
20% of gastric carcinoma cases. This observation is parallel to the 31.7% 
perineural infiltration reported in the study conducted by Luo Tianhang et al
110
. 
The expression of p53 and high Ki-67 LI was noted in 64% and 38% 
cases respectively. This proportion is comparable with the other studies 
conducted by N.E.Tzanakis et al
102 
in the Greek population, Kamran et al
112
 in 
the Arab population, Giovanni et al
107
 and Nobuyuki et al
101
. Several studies 
show p53 expression ranging from 34% to 65%. This fluctuation could be due 
to different methodologies used and to varying characteristics of the studied 
cases (Table 47). 
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TABLE 47 – COMPARISON OF p53 EXPRESSION AND Ki-67 LI IN 
WORLD STATISTICS 
 p53 positive p53 negative High Ki-67 LI Low Ki-67 LI 
Y. Maehara et al
111 
38.7% 61.3% NA NA 
Kamran et al
112 
75% 25% NA NA 
Zheng et al
113 
53% 47% 93% 7% 
Casasola et al
106 
NA NA 64.9% 35.1% 
Nobuyuki et al
101 
58% 42% 42% 58% 
Y. Kakeji et al
105 
54.2% 45.8% NA NA 
Giovanni et al
107 
NA NA 30.4% 69.6% 
Daniela Lazar et al
103 
41% 59% 54.1% 45.9% 
Czyzewska et al
108 
NA NA 64.4% 35.6% 
Y.E.Joo et al
100 
34.4% 65.6% 52.1% 47.9% 
N.E. Tzanakis et al
102 
65% 35% 46.2% 53.8% 
Current study 64% 36% 38% 62% 
 
CORRELATION OF p53 EXPRESSION WITH KNOWN CLINICO-
PATHOLOGICAL PROGNOSTIC FACTORS 
Y.Kakeji et al (1993) studied 96 gastric carcinomas in Japan and 
demonstrated statistically significant relationship between p53 expression and 
lymph node metastasis and vascular invasion and no relationship between stage, 
size, depth of invasion, grade and histological type
105
.  
Maehara et al (1999) studied 427 cases of gastric cancer in Japan and 
demonstrated statistically significant association between p53 expression and 
tumour size, site, lympho-vascular invasion, lymph node metastasis and 
stage
111
.  
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Nobuyuki et al (1999) studied p53 expression in 16 early gastric cancers 
and 15 advanced gastric cancers in Japan and found increased expression of p53 
in advanced gastric cancers and in node positive cases
101
. 
Karman et al (2004) studied 52 gastric cancers in Iran and demonstrated 
statistically significant association between tumour histologic type, depth of 
invasion and tumour grade and no significant association with lymph node 
metastasis
112
.  
Y.E.Joo et al (2006) studied 119 cases of gastric cancer in Korea and 
found significant association between p53 expression and depth of invasion. 
However, there was no association between p53 expression and tumour stage, 
status of lymph node and survival
100
. 
N.E.Tzanakis et al (2009) studied 93 gastric cancer patients in Greece and 
found statistically significant relationship between p53 expression and the 
tumour size, number of nodes involved, stage and the location of carcinoma 
within the stomach and no relationship between histological type and grade. 
Multivariate analysis showed decreased survival (22.3 months) for patients with 
carcinomas expressing p53 when compared to those not (44months)
102
. 
Daniela Lazar et al (2010) studied 61 gastric cancer patients in Romania 
and found statistically significant association between p53 expression and 
tumour grade, Lauren‟s histological type, depth of invasion and number of 
nodes involved and increased survival
103
. 
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In the present study, there was a direct significant association between 
tumour location and lymphatic invasion with p53 expression. Pan-gastric 
tumours and tumours of the distal stomach showed significantly increased 
percentage of cases showing p53 expression. p53 expression was increased in 
the elderly and there was a slight predominance in males and intestinal type 
tumours. 100% of mucinous carcinomas and N2 tumours showed p53 
expression. p53 positivity was seen to increase with increasing tumour grade, 
depth of invasion and stage, but statistically significant association could not be 
ascertained.  
In comparison with the above studies, this study also showed no 
statistically significant association between p53 expression and Borrmann gross 
type, tumour size, histological type, lymph node metastasis, vascular invasion 
and perineural infiltration. 
CORRELATION OF Ki-67 LABELING INDEX WITH KNOWN 
CLINICO-PATHOLOGICAL PROGNOSTIC FACTORS 
Giovanni de Manzonni et al (1998) studied 56 patients who underwent 
curative gastrectomy for advanced gastric cancer in Italy and demonstrated no 
significant association between Ki-67 labeling index and depth of tumour 
invasion, nodal status and histological type. They also found that the 
proliferative activity in advanced gastric cancers may not significantly influence 
survival except in elderly patients
107
. 
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Nobuyuki et al (1999) studied Ki-67LI in 16 cases of early gastric cancer 
and 15 cases of advanced gastric cancer in Japan and found significantly higher 
levels of Ki-67 labeling in the advanced gastric cancer group compared to the 
early gastric cancer group. No significant association was found between Ki-67 
LI and lymph node metastasis
101
. 
Czyzewska et al (2004) studied tumours from 45 gastric cancer patients 
in Poland and found a statistically significant association between Ki-67 LI and 
histological type, presence of lymph node metastasis and tumour differentiation 
and no association was found with depth of invasion and stage
108
. 
Casasola et al (2004) studied the prognostic value of Ki-67, Cyclin – D1, 
Cyclin – D3 and CDK4 in 74 cases of gastric cancer. The statistical results 
showed that only Ki-67 was an independent significant prognostic factor and 
correlated well with the length of survival
106
. 
Y.E.Joo et al (2006) studied 119 gastric cancers in Korea and found no 
association between Ki-67 labeling index and tumour size, depth of invasion, 
lymph node metastasis, stage and survival. Liu et al
114
 and Kanai et al
`115
 
reported that Ki-67 LI did not influence the prognosis in gastric cancer
100
.  
N.E. Tzanakis et al (2009) studied 93 gastric cancer cases and found 
significant association between the Ki-67 LI and lymph node metastasis and 
stage and no association was found with histological type
102
. 
Daniela Lazar et al (2010) studied 61 cases of gastric cancer in Romania 
and demonstrated a statistically significant association between Ki-67 LI and 
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age, tumour site, histological type and grade. No association was found with 
lympho-vascular invasion, depth of invasion, lymph node status and stage
116
. 
The 5-year survival rates of patients with low Ki-67 LI was 17.9% compared to 
the rate of 15.2% in patients with high LI. This difference in survival rates was 
not found to be statistically significant
116
. 
In the present study, there was a direct significant association between 
Ki-67 LI and perineural infiltration and vascular invasion. Higher Ki-67 LI was 
seen in mucinous carcinomas and signet ring cell carcinomas and low LI was 
seen in tubular and papillary carcinomas in concurrence with the  prognosis 
associated with these histological types. A slight predominance of higher LI was 
seen in males and in intestinal type. A progressive increase in the percentage of 
cases with high LI was seen with increasing grade, depth of invasion and nodal 
status which are proven prognostic factors.  
In comparison to the above studies, no significant association between 
Ki-67 LI and age, gender, tumour site, gross type, tumour size, lymphatic 
invasion and stage was observed. 
In the present study when high grade tumours were compared, it was 
found that the cases with nodal metastasis were positive for p53 
immunoreaction but had low Ki-67 LI and the cases with no nodal involvement 
were p53 negative with high Ki-67 LI. This perhaps indicates that p53 over-
expression has more bearing on nodal metastasis than Ki-67 LI.. It was also 
observed that a few low grade tumours with no nodal metastasis were p53 
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positive and had a low Ki-67 LI. These tumours require longer follow-up to rule 
out the possibility of latent nodal metastasis in view of their p53 expression. 
TABLE 48 - COMPARISON OF p53 EXPRESSION WITH Ki-67 LI 
 Mean Ki-67 LI 
p53 positive p53 negative 
Y.E.Joo et al 
100 
50.7 48.8 
Current study 29.362 18.361 
 
Y.E.Joo et al observed in their study that the mean Ki-67 LI value in p53 
positive tumours was not significantly higher than that of the p53 negative 
tumours
100
.  
However, the present study revealed that the mean Ki-67 LI value in p53 
positive tumours (29.362) was significantly (p=0.038) higher than that of p53 
negative tumours. P53 and Ki67 were found to be independent prognostic 
variables with different outcomes for the various clinico-pathological factors. 
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SUMMARY  
 
 
 
 
SUMMARY 
 The percentage of gastric carcinomas among the 9,541  surgical samples 
received at Madras Medical College in the year 2010 is 3.76%. 
 The distribution of non- neoplastic gastric lesions were 45%, benign were 
0.6% and malignant tumours were 54.39%. 
 Gastric cancers had a peak incidence in the age group of 51 – 60 years. 
 73% cases of gastric cancer were reported in males and 27% in females. 
 The most common location of gastric cancer was at the pyloro-antrum 
which constituted about 60.3% of the cases. 
 58.9% of tumours were less than 5 cm. 
 The most common histological type was tubular carcinoma which 
accounted for 53.9% of cases. 
 The most common Lauren‟s histological subtype was Intestinal 
carcinoma which accounted for 75.4% of cases. 
 G2 (moderately differentiated grade) was the most common grade 
accounting for 48.7% of cases. 
 46.2% of cases presented in T2 (invasion upto subserosa) and T3 
(invasion into the serosa) stage. 
 Nodal metastasis was observed in 56.4% of cases. 
70
 Most of the tumours (44.9%) presented in stage II. 
 Lymphatic invasion and vascular invasion was seen in 66.6% and19.3% 
of cases respectively. 
 Perineural infiltration was seen in 17.9% of cases. 
 Lymphocytic response was seen in 85.8% of cases and necrosis in 23% of 
cases. 
 P53 expression was seen in 64% of cases. 
 The mean Ki-67 LI was 25.4% 
 High Ki-67 Li was seen in 38% of cases and low LI in 62% of cases. 
  p53 expression showed statistically significant association with tumour 
location and lymphatic invasion. 
 An increase in the number of cases with p53 positivity was seen with 
increasing tumour grade, depth of infiltration, nodal metastasis, stage, 
mucinous and intestinal type carcinomas. 
 No statistically significant association between p53 expression and age, 
gender, Borrmann gross type, tumour size, vascular invasion, perineural 
infiltration and necrosis was found. 
 There was a direct significant association between Ki-67 LI and 
perineural infiltration and vascular invasion. 
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 There was increasing percentage of cases with high Ki-67 LI with 
increase in the grade, depth of infiltration, nodal metastasis, mucinous, 
signet ring and intestinal type carcinomas. 
 No significant association between Ki-67 LI and age, gender, tumour site, 
gross type, tumour size, stage, lymphatic invasion and necrosis was 
found. 
 The mean Ki-67 LI value was significantly higher in p53 positive 
tumours when compared to the LI value in p53 negative tumours. 
 No relationship was found between p53 and Ki-67. They were found to 
be independent prognostic factors. 
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 CONCLUSION 
 
 
 
 
CONCLUSION 
The incidence of gastric carcinoma was higher in this study group 
than the western population. Many patients presented in older age with 
predominance in males. p53 expression was found in 64% of cases which 
is similar to that of western population. The mean Ki-67 LI was lower 
when compared to the other test groups. p53 expression was significantly 
associated with tumour location and lymphatic invasion. The Ki-67 LI 
was associated with vascular invasion and perineural infiltration. An 
increasing  percentage of cases with p53 overexpression and high Ki-67 
LI  was noticed with increasing grade, depth of invasion, nodal status and 
stage. It was found that the mean Ki-67 LI value was significantly higher 
in p53 positive cases. It was also noticed that p53 over-expression had 
more bearing on nodal metastases than Ki-67 LI. Low grade tumours with 
p53 expression and no nodal metastasis require follow-up to rule out the 
possibility of latent nodal metastasis in view of their p53 expression. 
In conclusion, the role played by cell proliferation in the growth 
and aggressiveness of gastric tumours is complex and still not clarified. 
However, identifying the expression of p53 and Ki -67 LI in gastric 
carcinoma could be helpful to identify a group of patients at high risk of 
recurrence and poor survival. A larger sample size and follow up of these 
patients for 5 more years could throw more light on the role of p53 
mutation and Ki-67 LI as long term prognostic indicators. 
73
  
 
ANNEXURES 
 
 
 
 
ANNEXURE – I 
PROFORMA 
Case number             :                                                              Name  :                                                    
HPE number             :                                                              Age     : 
IP number                 :                                                              Sex      : 
Clinical history         : 
          Risk factors, if any   : 
          Clinical diagnosis     : 
Imaging                    : 
          Endoscopy                : 
          Previous HPE report: 
          Nature of specimen  :       Total gastrectomy/Subtotal gastrectomy/Others                                                                                                                        
          GROSS  
Proximal circumference :                            Greater curvature: 
Distal circumference      :                            Lesser curvature  : 
Tumour site                    : 
Tumour size                   : 
Tumour configuration    :                            Depth of invasion: 
           Margins                          :      Proximal   :                      Distal : 
Associated findings       : 
Total nodes dissected    : 
MICROSCOPY   
Histological type           : 
Histological grade        :      G1  /  G2  /  G4  /  G4 
Depth of invasion         : 
Margins                        :      Proximal :  Free  /  Involved 
                                             Distal       :  Free  /  Involved 
Lymphatic invasion      :      Present         /       Absent 
Venous invasion           :      Present         /     Absent  
Perineural invasion       :      Present         /     Absent 
Lymphocytic response :       Present         /     Absent 
Necrosis                        :      Present         /     Absent 
Associated findings: 
Total number of nodes dissected:                     Number of nodes involved: 
          Distant metastasis         : 
TNM staging                : 
IMMUNOHISTOCHEMISTRY 
P53 score  :    Intensity – 
                      % of tumour nuclei showing reaction - 
           Ki67 score:    Intensity –  
                                 % of tumour nuclei showing reaction -  
 
 
 
 
 
 
ANNEXURE - II 
 
WHO CLASSIFICATION OF GASTRIC TUMOURS 
 
EPITHELIAL TUMOURS 
 
NON-EPITHELIAL TUMOURS
Intraepithelial neoplasia – Adenoma 
 
Carcinoma 
Adenocarcinoma  
      Intestinal type  
      Diffuse type  
Papillary adenocarcinoma  
Tubular adenocarcinoma  
Mucinous adenocarcinoma 
Signet-ring cell carcinoma  
Adenosquamous carcinoma 
Squamous cell carcinoma  
Small cell carcinoma  
Undifferentiated carcinoma 
Others 
Carcinoid (well differentiated 
endocrine neoplasm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Leiomyoma  
Schwannoma  
Granular cell tumour 
Glomus tumour  
Leiomyosarcoma  
GI stromal tumour  
Benign  
Uncertain malignant potential  
Malignant  
Kaposi sarcoma  
Others 
Malignant lymphomas 
Marginal zone B-cell lymphoma of 
MALT-type 
Mantle cell lymphoma  
Diffuse large B-cell lymphoma  
Others 
 
SECONDARY TUMOURS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ANNEXURE III 
 
 TNM STAGING OF GASTRIC TUMOURS 
 
T – Primary Tumour 
TX - Primary tumour cannot be assessed 
T0 - No evidence of primary tumour 
Tis - Carcinoma in situ 
T1 - Tumour invades lamina propria or submucosa 
T2 - Tumour invades muscularis propria or subserosa 
T3 - Tumour penetrates serosa without invasion of adjacent structures 
T4 - Tumour invades adjacent structures 
 
N – Regional Lymph Nodes 
NX - Regional lymph nodes cannot be assessed 
N0 - No regional lymph node metastasis 
N1 - Metastasis in 1 to 6 regional lymph nodes 
N2 - Metastasis in 7 to 15 regional lymph nodes 
N3 - Metastasis in more than 15 regional lymph nodes 
 
M – Distant Metastasis 
MX - Distant metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
 
STAGE GROUPING 
Stage 0                       Tis                 N0                  M0 
Stage IA                      T1                 N0                  M0 
Stage IB                      T1                 N1                  M0 
                                    T2                  N0                  M0 
Stage II                       T1                  N2                  M0 
                                    T2                  N1                  M0 
                                    T3                  N0                  M0 
Stage IIIA                   T2                  N2                  M0 
                                    T3                  N1                  M0 
                                    T4                  N0                  M0 
Stage IIIB                    T3                 N2                  M0 
Stage IV                      T4                 N1, N2, N3    M0 
                                    T1, T2, T3     N3                  M0 
                                    Any T            Any N             M1 
 
 
 
 ANNEXURE IV 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
 
1. 4µ thick sections were cut from formalin fixed paraffin embedded tissue 
samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 
changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running 
tap water for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (citrate buffer) for 5 minutes x 2 
changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in citrate buffer for 5 minutes x 2 changes.  
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary 
antibody was applied over the sections and incubated for 1 hour (p53) and 
2 hours (Ki-67) respectively. 
15. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
16. The slides were covered with Super Enhancer for 30 minutes. 
17. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in citrate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1 
ml of DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with citrate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 seconds 
(1 dip). 
25. The slides are washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX. 
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 S.N HPEno Age Sex Proc Site Gross Size Hist. type Lauren Grade Depth Margins LI VI PNI Lym Nec LN Stage P53 Ki67 
1. 80/10 46 M STG Pyloro – antrum B – I 3 Diffuse DT G3 T3 Free A A A P A N0 II - - 
2. 110/10 65 F STG Pyloro – antrum B – I 2 Tubular  IT G2 T2 Free A A A P A N0 IB Positive 16.4% 
3. 151/10 60 F Pal G Pyloro – antrum B – III 6 Tubular IT  G2 T2 Distal A A A P A N0 IB Negative 9.3% 
4. 207/10 55 M STG Pyloro – antrum B - II 6 Diffuse DT G3 T4 Free P A A P A N1 IV - - 
5. 399/10 59 M STG Pyloro – antrum B – I 4 Mucinous IT G2 T3 Free P P A P A N0 II Positive 56.6% 
6. 558/10 60 M STG Body B – III 8 Tubular IT G2 T3 Distal P P A P A N1 II - - 
7. 638/10 58 M STG Pyloro – antrum B – III 5 Papillary IT G1 T3 Free P P A P P N1 IIIA Positive 41.1% 
8. 751/10 40 M STG Pyloro – antrum B – II 6 Diffuse DT G3 T2 Distal A A A P A N1 II Positive 18.2% 
9. 921/10 58 M STG Pyloro – antrum B – II 5 Tubular  IT  G2 T2 Free P P P A P N1 II Positive 13.4% 
10. 938/10 60 M TG OGJ B – II 5 Tubular IT G1 T3 Free P A A P A N1 IIIA - - 
11. 1238/10 62 M STG Pyloro - antrum B – III 6 Mucinous IT G3 T3 Free P A P P A N1 IIIA - - 
12. 1534/10 64 M STG Body B – II 11 Tubular IT G3 T3 Free P P A P P N2 IIIB Positive 52.3% 
13. 1802/10 35 F STG Pyloro - antrum B – III 5 Mucinous IT G2 T3 Free P P A P A N1 IIIA Positive 49.6% 
14. 1886/10 55 M STG Pyloro – antrum B – I 3 Mucinous IT G3 T3 Distal P P P P A N2 IIIB Positive 20.1% 
15. 2007/10 63 M STG Body B – I 8 Diffuse DT G3 T4 Free P A A P P N1 IV Positive 14.6% 
16. 2130/10 65 M STG Body B – III 9 Tubular IT  G2 T4 Distal P P A P A N2 IV Positive 15.8% 
17. 2190/10 55 M STG Body B – I 10 Papillary IT G1 T3 Free P P A P P N0 II Negative 17.6% 
18. 2456/10 47 F STG Pyloro - antrum B – II 5 Diffuse DT G3 T2 Free A A A A A N0 IB - - 
19. 2648/10 60 M STG Pyloro – antrum B – III 3 Tubular  IT G2 T2 Free A A A P A N0 IB Negative 14.1% 
20. 2678/10 70 M TG OGJ B – II 3 Tubular IT G2 T3 Proximal A A A P A N0 II Negative 13.5% 
21. 2906/10 33 M TG Diffuse B – IV - Diffuse DT G3 T3 Free P A A P A N1 IIIA Negative 6.9% 
22. 2922/10 50 M TG Diffuse B – IV - Diffuse DT G3 T3 Both A A A P A N0 II Positive 18.4% 
23. 3194/10 40 F STG Fundus B – II 6 Tubular IT G2 T2 Free P A A P A N1 II Negative 6.2% 
24. 3418/10 62 M STG Pyloro – antrum B – III 6 Tubular IT G2 T2 Free P A A P A N0 IB Positive 5.4% 
25. 3551/10 52 F STG Pyloro – antrum B – III 5 Diffuse DT G3 T3 Free A A A P A N0 II - - 
26. 3584/10 53 M STG Pyloro – antrum B - IV 2 Tubular IT G2 T2 Free A A A P A N0 IB Positive 38.8% 
27. 3667/10 52 M STG Pyloro - antrum B – II 3 Tubular IT G2 T2 Free A A A P A N0 IB Negative 10.5% 
28. 3702/10 73 M TG Diffuse B – IV - Mucinous IT G2 T3 Proximal P A A P A N1 IIIA Positive 11.6% 
29. 3729/10 35 F TG OGJ B – II 2 Tubular  IT G2 T4 Proximal P A A A A N1 IV - - 
 30. 3912/10 65 F TG Pyloro - antrum B - II 5 Tubular IT G2 T2 Free P A A P A N1 II - - 
S.n HPE no Age Sex Proc Site Gross Size Hist. type Lauren  Grade Depth  Margins LI VI PNI Lym  Nec LN Stage P53 Ki67 
31. 4002/10 43 M STG Pyloro - antrum B - IV 1.5 Diffuse DT G3 T2 Distal A A P A A N0 IB - - 
32. 4412/10 58 M STG Pyloro – antrum B – III 4.5 Tubular IT G1 T3 Free P A A P A N0 II Positive 9.2% 
33. 4501/10 45 M Pal G Pyloro - antrum B – I 3 Diffuse DT G3 T4 Free A A A P A N0 IV Negative 50.2% 
34. 4691/10 35 F TG Diffuse B – IV - SIgnet DT  G3 T3 Free P A A P A N1 IIIA Positive 18.3% 
35. 4821/10 62 F STG Pyloro - antrum B – II 3 Tubular IT G3 T3 Distal P A A A P N1 IIIA Positive 69.3% 
36. 4983/10 58 M STG Pyloro - antrum B – II 3.5 Tubular IT G2 T2 Distal P P P P A N1 II Positive 25.5% 
37. 4987/10 50 F STG Pyloro - antrum B – II 6 Mucinous IT G2 T2 Free P A A P A N1 II - - 
38. 5123/10 62 M TG Fundus B – II 12 Tubular IT G3 T2 Proximal P A P P P N0 II Positive 27.8% 
39. 5205/10 62 F TG OGJ B – II 1.5 Tubular IT G1 T2 Free A A A P A N1 II Negative 8.1% 
40. 5315/10 50 M STG Pyloro - antrum B - III 4 Mucinous IT G2 T2 Free P A A P A N1 II - - 
41. 5376/10 39 M STG Pyloro - antrum B – II 4.5 Tubular IT G2 T2 Free A A A A A N0 IB - - 
42. 5445/10 50 M STG Pyloro - antrum B – II 5 Mucinous IT G2 T2 Free A A A P P N0 IB - - 
43. 5489/10 73 M STG Pyloro - antrum B - III 3 Tubular IT G2 T2 Free P A A P A N0 II - - 
44. 5716/10 54 M STG Body B – II 2 Tubular IT G3 T2 Free P A A P P N1 II Positive 17.3% 
45. 5743/10 50 F STG Body EGC - III 4 Signet DT G3 T1 Free A A A P A N0 IA - - 
46. 5804/10 48 M STG Pyloro - antrum B – II 6.5 Mucinous IT G2 T3 Free P A A P A N2 IIIB Positive 25.7% 
47. 5933/10 28 F TG OGJ B – I 6 Signet DT G3 T2 Proximal P P P P A N0 IB Negative 28.3% 
48. 6093/10 59 M STG Body B – III 5 Tubular IT G2 T2 Free P A P P A N1 II - - 
49. 6320/10 65 M STG Pyloro - antrum B – I 4 Papillary IT G1 T3 Distal P A A P A N1 IIIa - - 
50. 6331/10 50 F TG OGJ B – III 6 Tubular IT G2 T2 Proximal A A A P A N0 IB Negative 7.1% 
51. 6372/10 23 F STG Pyloro - antrum B – III 3 Tubular IT G2 T2 Free P A A P A N1 II - - 
52. 6454/10 60 M STG Pyloro - antrum B – III 6 Tubular IT G3 T3 Distal P A A P P N1 IIIA Positive 16.1% 
53. 6486/10 75 M STG Body B - III 5 Mucinous  IT G2 T2 Distal P A P P A N0 IB Positive  44.8% 
54. 6503/10 73 M STG Pyloro - antrum B - IV 3 Tubular IT G2 T3 Free P A A P A N0 II Positive 10.2% 
55. 6597/10 37 M STG Pyloro - antrum B – II 3 Tubular IT G2 T2 Free A A A P A N0 IB Negative 43.1% 
56. 6723/10 75 M STG Pyloro - antrum B – II 6 Signet DT G3 T3 Free P P P P A N1 IIIA - - 
57. 6900/10 80 M STG Pyloro - antrum B - III 14 Tubular IT G2 T3 Free P A A P A N0 II - - 
58. 7127/10 60 M STG Pyloro - antrum B – I 4 Tubular IT G1 T3 Free P A A P A N1 IIIA Positive 24.8% 
 59. 7165/10 60 M STG Body B – II 6 Papillary  IT G1 T2 Free P A A P P N1 II Negative  9.8% 
60. 7176/10 50 M STG Body B - IV 5 Tubular IT G3 T3 Free A A A P A N0 II - - 
S.n HPEno  Age Sex Proc Site Gross Size Hist. type Lauren Grade Depth Margins LI VI PNI Lym  Nec LN Stage P53 Ki67 
61. 7239/10 35 M TG Body B – III 5 Signet DT G3 T3 Distal P P P P A N1 IIIA Negative 37.2% 
62. 7306/10 64 F STG Pyloro - antrum B - II 8 Diffuse DT G3 T2 Free P A A P A N1 II - - 
63. 7830/10 65 F TG OGJ B - III 6 Diffuse DT G3 T2 Free P A A A A N1 II - - 
64. 8338/10 50 M STG Pyloro - antrum B – II 6 Tubular IT G1 T2 Free A A A P P N0 IB Positive 4.9% 
65. 8586/10 49 F TG OGJ B – II 4 SCC - G2 T2 Proximal A A A A A N1 II - - 
66. 8612/10 50 M STG Body B – II 3 Tubular IT G1 T2 Free A A A A A N1 II Negative 3.9% 
67. 8755/10 55 M STG Pyloro - antrum B – I 2 Tubular IT G2 T2 Free P P A P P N1 II Positive 64.5% 
68. 8808/10 60 M PSTG Body B – III 4 Tubular IT G2 T3 Distal P P P P A N1 IIIA Positive 48.7% 
69. 8829/10 65 F STG Pyloro - antrum B – II 5 Tubular IT  G2 T3 Free P A P P A N2 IIIB Positive 37.6% 
70. 9004/10 55 M TG OGJ B – I 9 Tubular IT G2 T3 Free P A A P P N1 IIIA Negative 19.3% 
71. 9011/10 45 F STG Pyloro - antrum B – II 5 Diffuse DT G3 T2 Free P A A A A N0 IB Positive 23.4% 
72. 9154/10 58 M STG Pyloro - antrum B – II 3 Tubular IT G2 T3 Free A A A P A N0 II - - 
73. 9180/10 45 M STG Pyloro - antrum B – III 2.5 Signet DT G3 T3 Free A A A P A N0 II - - 
74. 9300/10 65 M STG Pyloro - antrum B – II 9 Tubular IT G2 T3 Free P A A P P N1 IIIA Negative 26.1% 
75. 9316/10 55 M STG Pyloro - antrum B – II 8 Papillary IT G1 T2 Free P A A P P N1 II Negative 19.3% 
76. 9332/10 65 M TG Body B – III 8 Tubular IT G3 T3 Free A A A P P N0 II Positive 75.3% 
77. 9400/10 55 M STG Body B – III 2 Tubular IT G2 T3 Proximal P A P P P N0 II Positive 23.9% 
78. 9437/10 65 M STG Pyloro - antrum B – III 8 Mucinous  IT G3 T3 Free P A A A A N1 IIIA - - 
  
KEY TO MASTERCHART 
Proc       –    Procedure 
Hist.      –    Histological 
LI          –    Lymphatic invasion 
VI          –   Vascular invasion 
PNI        –   Perineural invasion 
Lym       –   Lymphocytic response 
Nec        –   Necrosis 
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STG      –     Sub-Total Gastrectomy 
Pal G     –    Palliative Gastrectomy 
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EGC       –    Early Gastric Cancer 
IT           –    Intestinal Type 
DT          –    Diffuse Type 
G           –     Grade 
T            –    Tumour depth 
P             -      Present 
A           –     Absent 
N            -     Node 

ABSTRACT 
AIM: 
The variable prognosis of gastric cancer within a pathological stage necessitates the 
identificationof subgroups of patients with a more aggressive disease. The role of p53 and 
Ki67 expression in gastric carcinoma is far from being fully established. The aim of the 
present study was to identify the incidence and distribution of gastric carcinoma in 
patients admitted in the Government General Hospital, Chennai in the year 2010 and to 
evaluate the expression of p53 and Ki67 in gastric cancer and correlate the findings with 
several clinico-pathological features and prognosis. 
MATERIALS AND METHODS: 
Formalin-fixed paraffin-embedded tissue samples from 50 patients treated by gastric 
resection for gastric carcinoma in the year 2010 were studied by immunohistochemistry, 
using monoclonal antibodies to p53 and Ki67. The results were correlated with clinico-
pathological features. 
RESULTS: 
p53 over-expression was significantly related with tumour location and lymphatic 
invasion. Higher Ki-67 labeling index correlated significantly with vascular invasion and 
perineural infiltration. Increasing p53 expression and Ki-67 labeling index was associated 
with increasinggrade, depth of infiltration, nodal stage and TNM stage. The mean Ki-67 
labeling index was higher in p53 positive cases.p53 and Ki-67 were identified as 
independent prognostic factors. 
 
CONCLUSION:  
The role played by cell proliferation in the growth and aggressiveness of gastric tumours 
is complex and still not clarified. Identifying the overexpression of p53 and Ki -67 LI in 
gastric carcinoma could be useful as independent prognostic markers in identification of 
patients at high risk of recurrence and poor survival. Follow up of these patients for 5 
more years could throw more light on the role of p53 mutation and Ki-67 LI as long term 
prognostic indicators. 
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